Non-Small Cell Lung Cancer

On this page

Quick Reference

RxDrug of choiceOsimertinib 80 mg daily for EGFR-mutant; Lorlatinib 100 mg daily for ALK-positive; Pembrolizumab 200 mg q3w for PD-L1 ≥50%

AltAlternativesAlectinib 600 mg BID for ALK; Amivantamab + Lazertinib for EGFR; Atezolizumab for PD-L1; Sotorasib for KRAS G12C

⊘AvoidBevacizumab and pemetrexed in squamous NSCLC; Datopotamab deruxtecan in squamous histology

DxTest of choiceComprehensive NGS panel (tumor tissue) + PD-L1 IHC (22C3)

ScKey scoreECOG performance status (0-2 for active treatment)

→When to referMultidisciplinary discussion (thoracic surgery, radiation oncology, medical oncology) before any treatment; HIV specialist for PLWH

NSCLC management is driven by stage, molecular profile, and PD-L1 expression; targeted therapy and immunotherapy have dramatically improved outcomes, with 5-year PFS exceeding 60% in ALK-positive disease on lorlatinib.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the United States, accounting for approximately 85% of all lung cancers. The disease encompasses distinct histologic subtypes (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) and a growing list of actionable driver mutations that have transformed treatment from one-size-fits-all chemotherapy to biomarker-driven precision medicine. Prognosis varies dramatically by stage, molecular profile, and performance status, 5-year survival for advanced disease historically <10% but now exceeding 60% in ALK-positive patients on modern targeted therapy. This overview provides a clinically actionable framework for evaluation and management, integrating the latest trial data on targeted agents, immunotherapy, and multidisciplinary care.

Overview and Recommendations

Background

•NSCLC is the most common histologic type of lung cancer, comprising adenocarcinoma (~75% of cases), squamous cell carcinoma, and large cell carcinoma. It is the leading cause of cancer-related mortality in the US, with a 5-year survival rate for advanced disease historically <10% but improving substantially with modern therapies.
•The molecular taxonomy of NSCLC is defined by mutually exclusive driver mutations: EGFR mutations (15% overall, 48% in Asian adenocarcinomas), KRAS mutations (26% in Western adenocarcinomas), ALK rearrangements (3-7%), and others including BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2, and ROS1. These drivers dictate targeted therapy selection and are enriched in never-smokers and younger patients.
•The treatment paradigm has shifted from one-size-fits-all platinum-based chemotherapy to biomarker-driven precision medicine and immunotherapy. For advanced disease, first-line therapy now includes targeted agents for actionable mutations, PD-1/PD-L1 checkpoint inhibitors alone or combined with chemotherapy, and anti-angiogenic agents, a transformation driven by landmark trials such as KEYNOTE-189, ALEX, CROWN, and MARIPOSA.
•Unresectable stage III NSCLC is managed with concurrent chemoradiotherapy followed by consolidation durvalumab for 12 months, which improved 5-year overall survival to 42.9% vs 33.4% in the PACIFIC trial. The LAURA trial extended this paradigm to EGFR-mutant stage III disease, with osimertinib after chemoradiotherapy reducing CNS progression risk by 83%.
•Prognostic factors include stage, histology (nonsquamous more favorable), PD-L1 expression, and presence of driver mutations. ALK-positive disease has the most favorable prognosis, with 5-year PFS rate of 60% on lorlatinib (CROWN). TP53 co-mutations and detectable ctDNA at baseline predict worse outcomes even with targeted therapy.

Evaluation

•Suspect NSCLC in any patient aged >50 with a new persistent cough, hemoptysis, dyspnea, or unexplained weight loss >5% within 6 months, especially in smokers (ever-smoker status is a risk factor for early mortality) or people living with HIV (PLWH) who have higher incidence and mortality.
•Ask about smoking history (pack-years), occupational exposures (asbestos, radon), family history of lung cancer, and symptoms of metastatic disease including headache, bone pain, focal neurologic deficits, and seizures. In patients with EGFR or ALK mutations, specifically inquire about neurologic symptoms suggesting leptomeningeal disease.
•Examine for supraclavicular or scalene lymphadenopathy, decreased breath sounds, dullness to percussion (pleural effusion), clubbing, Horner syndrome (Pancoast tumor), hoarseness (recurrent laryngeal nerve involvement), and signs of superior vena cava syndrome. Assess performance status using scale (0-2 for active treatment).
•Order contrast-enhanced CT chest extending through the liver and adrenals as initial imaging. Also obtain 18F-FDG PET/CT for suspected stage I-III disease to detect occult distant metastases in 10-15% of patients and to refine radiotherapy target volumes.
•Obtain brain MRI (or contrast CT if MRI contraindicated) for stage II-III disease or any neurologic symptoms, given 20-30% prevalence of brain metastases at diagnosis. For ALK-positive patients, baseline brain imaging is critical as CNS progression is common with less CNS-penetrant TKIs.
•Perform tissue biopsy via core needle, endobronchial ultrasound (EBUS), or surgical biopsy to obtain adequate tissue for both histologic classification and molecular testing. The ASCO guideline recommends 'reasonable efforts to obtain more tissue than what is contained in a routine cytology specimen' to enable comprehensive genomic profiling.
•Histologically classify as squamous or non-squamous using immunohistochemistry (TTF-1, napsin A for adenocarcinoma; p40, CK5/6 for squamous). This distinction is therapeutically critical: pemetrexed and bevacizumab are contraindicated in squamous histology, and datopotamab deruxtecan should be avoided in squamous NSCLC.
•Order comprehensive next-generation sequencing (NGS) on tumor tissue to test for EGFR (exon 19 del, L858R, T790M), ALK rearrangements, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2 mutations, KRAS G12C, and STK11/LKB1. ESMO recommends NGS as the preferred approach because it conserves tissue and captures all actionable alterations in a single assay.
•Order PD-L1 immunohistochemistry using validated assays (22C3, 28-8, SP142, SP263) to determine eligibility for immune checkpoint inhibitors. PD-L1 tumor proportion score (TPS) ≥50% qualifies for pembrolizumab monotherapy; TPS ≥1% is used in combination regimens.
•Target a turnaround time (TAT) of ≤2 weeks for EGFR and ALK testing. Real-world data show that TAT >2 weeks multiplies the odds of initiating suboptimal non-targeted therapy more than sixfold (OR 6.02) and is associated with worse median progression-free survival (9 vs 11 months).
•Stage according to 8th edition TNM classification using the T size cutoffs: T1 ≤3 cm, T2 3-5 cm, T3 5-7 cm, T4 >7 cm. Accurate staging determines curative versus palliative intent. For clinical stage I candidates for , PET/CT alone is sufficient for mediastinal staging; after negative EBUS, confirmatory mediastinoscopy can be omitted (unforeseen N2 rate ~8%).
•Assess for sarcopenia (CT-defined skeletal muscle index) and elevated BMI (≥25 kg/m²), which increase risk of platinum-associated adverse events. In such patients, dose using CKD-EPI GFR rather than Cockcroft-Gault to avoid toxicity.

Management

•For stage I-IIIA resectable NSCLC, perform lobectomy with mediastinal lymph node dissection. For patients who are not surgical candidates, stereotactic ablative radiotherapy ( ) is an alternative. Adjuvant platinum-based chemotherapy is recommended for stage II-IIIA and selected IB with high-risk features.
•For stage IB-IIIA EGFR-mutant (exon 19 deletion or L858R) NSCLC after complete resection, administer adjuvant 80 mg orally once daily for 3 years. In the ADAURA trial, 4-year DFS was 70% vs 29% with placebo (HR 0.23).
•For stage II-IIIA NSCLC with PD-L1 tumor cell ≥50% after platinum-based chemotherapy, consider adjuvant 840 mg IV every 2 weeks for 1 year (IMpower010: OS HR 0.43 in this subgroup).
•For unresectable stage III NSCLC, deliver concurrent chemoradiotherapy (e.g., cisplatin 50 mg/m² days 1,8,29,36 + etoposide 50 mg/m² days 1-5, 29-33 with thoracic RT 60-66 Gy). Follow with consolidation 10 mg/kg IV every 2 weeks for 12 months if no progression (PACIFIC: 5-year OS 42.9% vs 33.4%). For EGFR-mutant stage III, consider osimertinib after CRT (LAURA: CNS progression HR 0.17).
•For stage IV EGFR-mutant NSCLC (exon 19 del or L858R), initiate first-line 80 mg daily. Alternatively, amivantamab 1050 mg (for <80 kg) or 1400 mg (≥80 kg) IV weekly for 4 weeks then every 2 weeks plus 240 mg daily, this combination improved PFS over osimertinib in high-risk subgroups (TP53 co-mutation HR 0.65, liver metastases HR 0.58, detectable ctDNA HR 0.68) in MARIPOSA.
•For stage IV ALK-positive NSCLC, initiate first-line 100 mg orally once daily. In the CROWN trial, 5-year PFS rate was 60% vs 8% with crizotinib (HR 0.19). 600 mg twice daily is an alternative with 5-year OS rate of 62.5% vs 45.5% with crizotinib (ALEX).
•For stage IV ROS1-positive NSCLC, use 600 mg daily or 250 mg twice daily. For BRAF V600E-mutant, use 150 mg twice daily plus 2 mg daily. For MET exon 14 skipping, use 400 mg twice daily or 500 mg daily.
•For stage IV NSCLC with PD-L1 TPS ≥50% and no actionable driver mutation, use 200 mg IV every 3 weeks or 400 mg every 6 weeks, or 790 mg subcutaneously every 6 weeks. Monotherapy yields median OS 30 months vs 14.2 months with chemotherapy (KEYNOTE-024).
•For stage IV non-squamous NSCLC with PD-L1 TPS <50% or any level, use pembrolizumab 200 mg IV every 3 weeks plus 500 mg/m² and platinum (cisplatin 75 mg/m² or carboplatin AUC 5-6) every 3 weeks for 4 cycles, followed by pembrolizumab plus pemetrexed maintenance (KEYNOTE-189: HR 0.56 for OS).
•For stage IV squamous NSCLC, use pembrolizumab 200 mg IV every 3 weeks plus carboplatin AUC 6 and 200 mg/m² or 100 mg/m² weekly for 4 cycles, then pembrolizumab maintenance (KEYNOTE-407: 5-year OS 18.4% vs 9.7%).
•For patients with HER2 mutations (2-4% of NSCLC), administer 5.4 mg/kg IV every 3 weeks; ORR 49% (DESTINY-Lung02). For HER2 overexpression (IHC 3+), ORR 34.1% (DESTINY-Lung01).
•For KRAS G12C-mutant NSCLC, use 960 mg daily or 600 mg twice daily. In patients with STK11 co-mutation, consider dual checkpoint blockade (CTLA-4 + PD-1/PD-L1) which improved OS over single-agent PD-1/PD-L1 (HR 0.67).
•For patients who progress on EGFR-TKIs, a network meta-analysis recommends platinum-based chemotherapy combined with an anti-PD-1/PD-L1 agent plus an anti-VEGF agent (or bispecific antibody) or with amivantamab (PFS HR 0.51 and 0.48 vs chemotherapy alone).
•Monitor for immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies, dermatitis) during immunotherapy. For grade ≥3 toxicity, hold treatment and administer corticosteroids (prednisone 1-2 mg/kg/day or equivalent). For grade 2 pneumonitis, hold and consider steroids if persistent.
•Avoid non-platinum doublets, single-agent chemotherapy, and empirical targeted therapy without biomarker testing. In patients with sarcopenia and elevated BMI (≥25 kg/m²), dose carboplatin using CKD-EPI GFR rather than Cockcroft-Gault to reduce toxicity. In people living with HIV, coordinate with HIV specialist to manage drug-drug interactions between antiretrovirals and cancer therapies; do not withhold standard NSCLC therapy based on HIV status alone.

Board Review — High Yield

•ADAURA trial, Adjuvant osimertinib for 3 years after resection of EGFR-mutant stage IB-IIIA NSCLC improved DFS (HR 0.23).
•PACIFIC trial, Consolidation durvalumab for 12 months after concurrent chemoradiotherapy for unresectable stage III NSCLC improved 5-year OS (42.9% vs 33.4%).
•KEYNOTE-189, Pembrolizumab + pemetrexed/platinum improved OS in metastatic nonsquamous NSCLC regardless of PD-L1 (HR 0.56).
•ALEX trial, Alectinib 600 mg BID superior to crizotinib in ALK-positive NSCLC (median OS 81.1 vs 54.2 months).
•CROWN trial, Lorlatinib 100 mg daily achieved 5-year PFS rate of 60% in ALK-positive NSCLC (HR 0.19 vs crizotinib).
•MARIPOSA trial, Amivantamab + lazertinib improved PFS over osimertinib in EGFR-mutant NSCLC, especially in TP53 co-mutation and liver metastases subgroups.
•NCCN guidelines recommend testing for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, KRAS G12C, and PD-L1 in all advanced non-squamous NSCLC.
•Molecular testing TAT ≤2 weeks is critical; longer delays increase odds of suboptimal therapy (OR 6.02).
•Squamous histology contraindicates pemetrexed, bevacizumab, and datopotamab deruxtecan.
•STK11/LKB1 mutations predict primary resistance to PD-1 monotherapy; dual CTLA-4 + PD-1/PD-L1 blockade improves OS (HR 0.67).

Deep Dive — Evidence Details

Definition and Epidemiology

▸NSCLC is the leading cause of cancer-related mortality in the United States.
▸Incidence increases with age and is expected to rise further as Western populations age.
▸People living with HIV have an elevated incidence of NSCLC and worse outcomes, highlighting the need for tailored screening and care.

HY High Yield: Elderly patients represent a growing proportion of NSCLC cases; consider geriatric assessment to guide treatment decisions, as chronological age alone does not predict functional reserve [3].

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is a type of epithelial lung cancer other than small-cell lung cancer (SCLC). Non-small-cell lung cancer accounts for about 85% of all lung cancers. A — Non-small-cell lung cancer — Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is a type of epithelial lung cancer other than small-cell lung cancer (SCLC). No...Wikipedia ↗

Non-small cell lung cancer (NSCLC) is the most common histologic type of lung cancer, comprising several subtypes including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC is the leading cause of cancer-related mortality in the United States ^[12]^B2b. The disease is particularly common in the elderly population, and its incidence is expected to rise further with the aging of Western populations ^[3]^A1c. People living with HIV (PLWH) are diagnosed with NSCLC at an increased rate compared with the general population and experience higher mortality due to delayed diagnoses, advanced stage at presentation, and treatment disparities ^[1]^A1c.

Aspect	Finding	Reference
Mortality	Leading cause of cancer-related death in the US	^[12]^B2b
Age distribution	Very common in the elderly; incidence expected to increase with aging	^[3]^A1c
HIV comorbidity	Increased incidence and higher mortality in PLWH	^[1]^A1c

The epidemiology of NSCLC is shaped by shifting demographics: an aging population will drive a growing burden of disease, and the higher risk in immunosuppressed populations underscores the role of immune surveillance in lung carcinogenesis. The following section details the established risk factors and prevention strategies for NSCLC.

Pearl: The rising incidence of NSCLC in elderly patients compels clinicians to integrate geriatric assessment into treatment planning, as age itself influences both tumor biology and therapeutic tolerance ^[3]^A1c.

Risk Factors and Prevention

▸Tobacco smoking is the predominant risk factor for NSCLC, and ever-smoker status is associated with early mortality.
▸HIV infection is an additional risk factor; NSCLC is the second most common non-AIDS-defining cancer in people with HIV.
▸Risk factors for early mortality include male sex, age >70 years, weight loss, poor performance status, and advanced stage.

The incidence of NSCLC is driven by a well-characterized set of risk factors, with tobacco smoking as the predominant cause. In the KBP-2020 cohort, ever-smoker status was identified as a risk factor for early mortality ^[33]^B2b, and smoking is also recognized as a modifiable risk factor contributing to the emergence of new morbidities in people with HIV (PWH) who develop NSCLC ^[24]^B3b.

Established Risk Factors

Tobacco smoking remains the most important preventable cause. In the French nationwide KBP-2020 cohort, ever-smoker status was among the risk factors for early mortality (3-month mortality rate 20.3%) ^[33]^B2b. HIV infection is an additional risk factor: PWH are at increased risk for non-AIDS-defining cancers (NADCs), and NSCLC is the second most common NADC, comprising 22% of NADC cases in the CNICS cohort ^[24]^B3b.

Other factors associated with early mortality in the KBP cohort include male sex, age >70 years, weight loss >10 kg, symptomatic disease at diagnosis, poor Eastern Cooperative Oncology Group performance status (≥1), large-cell carcinoma or not otherwise specified histology, and stage ≥IIIC disease ^[33]^B2b. These factors reflect both the biological aggressiveness of the tumor and the patient's baseline health.

Factor	OR/RR/HR (with CI)	Plain-English meaning	Independent?	Reference
Male sex	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Age >70 years	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Ever smoker	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Weight loss >10 kg	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Symptomatic disease at diagnosis	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
PS ≥1	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Large-cell carcinoma or NOS	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b
Stage ≥IIIC disease	Not reported	Associated with higher early mortality	Not reported	^[33]^B2b

Note: The KBP study reported risk factors for 3-month mortality, not for incidence. Specific odds ratios were not provided in the abstract ^[33]^B2b.

Prevention

Prevention of NSCLC centers on tobacco avoidance and cessation. Among PWH, smoking cessation may reduce the risk of developing NSCLC and other NADCs ^[24]^B3b. The cumulative incidence of grade ≥3 chronic health conditions at 20 years was highest for PWH with NSCLC (54%) compared with other NADCs, underscoring the need for aggressive risk factor modification in this population ^[24]^B3b.

Pearl: The most effective preventive strategy for NSCLC is smoking cessation; among PWH, integrated care that addresses smoking and other modifiable risk factors is critical to reduce the high burden of chronic morbidity.

Genetics and Hereditary Predisposition

▸Germline EGFR T790M, TP53, BRCA1/2, and CDKN2A mutations are associated with NSCLC, particularly in young patients (<50 years) and never-smokers.
▸NCCN and ESMO guidelines recommend germline EGFR T790M testing when de novo somatic T790M is detected.
▸Identification of a germline mutation triggers cascade testing for relatives and may alter surveillance and treatment strategies.

HY High Yield: Young patients (<50 years) with NSCLC have a higher probability of harboring a targetable genomic alteration (up to 84% in one Asian cohort) and more often carry gene fusions (ALK, ROS1, RET), comprehensive genomic profiling is strongly recommended [42].

Beyond population-level risk factors, a subset of NSCLC arises in the context of an inherited cancer predisposition syndrome, a recognition that carries direct implications for the patient, their siblings, and offspring. Although lung cancer has not traditionally been considered a highly heritable malignancy, emerging data, particularly in young patients, reveal germline alterations that may drive carcinogenesis and guide management.

Recognized Hereditary Lung Cancer Syndromes

The strongest evidence links several germline mutations to NSCLC susceptibility, especially in patients diagnosed at a young age, those with multiple primary cancers, or never-smokers. The table below summarizes the key syndromes and their clinical relevance.

Gene	Syndrome	Key Features in NSCLC	Testing Recommendation
EGFR T790M	Germline EGFR T790M	De novo somatic T790M on multiple biopsies; family history of lung cancer; bilateral or multifocal disease	NCCN and ESMO recommend germline analysis when de novo somatic T790M is detected ^[42]^B2a^[49]^C4
TP53	Li-Fraumeni syndrome	Early-onset NSCLC; often with additional cancers (breast, sarcoma, brain); up to 90% of Li-Fraumeni lung cancers harbor an oncogenic driver, most commonly EGFR exon 19 deletion ^[42]^B2a	Germline TP53 testing in patients with suggestive personal/family history
BRCA1/BRCA2	Hereditary breast and ovarian cancer	Pathogenic variants found in 1% of NSCLC (64/6220); prevalence significantly higher in patients aged <50 years ^[42]^B2a	Consider germline testing in early-onset disease, especially with family history of breast/ovarian cancer
CDKN2A	-pancreatic cancer syndrome	Associated with synchronous lung and pancreatic primaries; case example: CDKN2A p.I49T variant identified via germline testing after ctDNA revealed an EGFR L858R lung primary ^[48]^C4	Germline testing in patients with personal/family history of melanoma or pancreatic cancer

When to Suspect a Germline Mutation

A germline etiology should be considered in the following scenarios:

Age at diagnosis ≤ 50 years, the frequency of targetable genotypes drops sharply above age 50, and young patients more often harbor gene fusions or uncommon EGFR mutations ^[42]^B2a.
Never-smoker status, adenocarcinoma in never-smokers has a higher prevalence of oncogenic drivers, some of which (e.g., EGFR T790M) may be germline ^[42]^B2a^[56]^D5.
Family history of lung cancer, familial aggregation ranges from 1% to 30% across studies; a positive family history should prompt consideration of germline testing ^[42]^B2a.
Multiple primary lung cancers, bilateral or metachronous tumors, especially when each harbors a similar driver mutation, raise suspicion for a germline origin ^[49]^C4.
De novo T790M mutation, when a somatic T790M is detected in the absence of prior EGFR-TKI exposure, germline testing is indicated ^[42]^B2a^[49]^C4.

Guidelines for Germline Testing

Current NCCN and ESMO guidelines explicitly recommend germline analysis of EGFR T790M in patients with de novo somatic EGFR T790M mutation ^[42]^B2a^[49]^C4. For other genes, no formal consensus exists, but expert opinion supports case-by-case discussion on molecular tumor boards, particularly when a young patient harbors a suspicious somatic mutation (e.g., TP53, BRCA1/2) ^[42]^B2a. The increasing availability of next-generation sequencing (NGS) in clinical practice facilitates simultaneous germline and somatic assessment, and ctDNA testing can serve as a minimally invasive gateway to identify actionable variants that may prompt germline workup ^[48]^C4^[59]^C4.

Clinical Implications

Identifying a germline mutation has direct consequences:

Cascade testing, first-degree relatives can be offered predictive testing and enhanced surveillance (e.g., low-dose CT for lung cancer, breast MRI for BRCA carriers).
Treatment selection, germline EGFR T790M may influence the choice of EGFR-TKI; patients with Li-Fraumeni syndrome require careful monitoring for second malignancies.
Prognosis, concurrent TP53 mutation, common in young patients, confers worse outcomes with targeted therapy (e.g., median PFS 5.3 months in EGFR/TP53-mutant young patients) ^[42]^B2a.

The recognition of hereditary predisposition thus shifts management from a single-patient focus to a family-centered approach. The somatic molecular landscape of these tumors, especially the high frequency of targetable fusions in young patients, is explored in the next section on Histopathology and Molecular Biology.

Pearl: In any patient with NSCLC diagnosed at age ≤50 years, a never-smoker, or with a family history of lung cancer, consider germline testing for EGFR T790M, TP53, and BRCA1/2, a positive result mandates cascade testing for at-risk relatives.

Histopathology and Molecular Biology

▸Histologic subtype (adenocarcinoma vs squamous cell) is a critical predictive factor for chemotherapy and antibody-drug conjugate efficacy, with pemetrexed and datopotamab deruxtecan showing benefit only in nonsquamous NSCLC.
▸Driver mutations in EGFR, KRAS, ALK, BRAF, and others are mutually exclusive and vary significantly by ethnicity and histology, guiding targeted therapy selection.
▸Prognostic mRNA expression signatures can provide independent risk stratification beyond clinical staging, with more validated signatures for adenocarcinoma than squamous cell carcinoma.

HY High Yield: Mutual exclusivity of EGFR, KRAS, and ALK mutations means that if one is found, the other two are almost certainly absent, this simplifies testing algorithms and avoids duplicative testing.

Beyond the hereditary predisposition discussed above, the vast majority of NSCLC driver mutations are somatic and exhibit striking patterns by histology, ethnicity, and smoking history. These patterns define the molecular taxonomy of NSCLC and directly guide biomarker testing and treatment selection.

Histologic Subtypes

NSCLC is broadly divided into two main histologic categories: nonsquamous (predominantly adenocarcinoma, plus large-cell carcinoma and other rarer types) and squamous cell carcinoma (SCC). Adenocarcinoma is the most common subtype, accounting for approximately 75% of cases, and is the histology in which most targetable driver mutations are found ^[67]^A1b. SCC is more strongly associated with smoking and harbors a distinct molecular profile, including frequent TP53 mutations and alterations in the PI3K/AKT pathway ^[6]^B2a.

Histology is a critical predictive factor for chemotherapy selection. The phase III study that established /pemetrexed as a standard regimen for nonsquamous NSCLC showed superior survival over cisplatin/ in adenocarcinoma (median OS 12.6 versus 10.9 months) and large-cell carcinoma (10.4 versus 6.7 months), whereas in SCC cisplatin/gemcitabine was superior (10.8 versus 9.4 months) ^[69]^A1b. Similarly, / achieved a higher objective response rate in SCC (41% versus 24%) compared with solvent-based , but no difference in nonsquamous histology ^[68]^A1b. The antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) demonstrated improved PFS over only in nonsquamous NSCLC (median 5.5 versus 3.6 months; HR 0.63), with a harmful trend in SCC (HR 1.41) ^[67]^A1b. These histology-dependent effects underscore the biologic differences between subtypes.

Molecular Drivers

Driver mutations that activate oncogenes or inactivate tumor suppressor genes are present in over 80% of adenocarcinomas and approximately 47% of SCCs ^[6]^B2a. The most common and clinically actionable mutations are mutually exclusive, supporting the concept of oncogene addiction.

Table 1. Incidence of Key Driver Mutations by Histology and Ethnicity (adapted from ^[6]^B2a)

Gene	Western/ADC	Asian/ADC	Western/SCC	Asian/SCC
EGFR	19.2%	47.9%	3.3%	4.6%
KRAS	26.1%	11.2%	6.4%	1.8%
EML4-ALK	6.4%	5.4%	4.5%	0%
BRAF	3.3%	,	0.2%	,
LKB1	16.2%	4.0%	9.5%	0.0%
PTEN	6.0%	1.6%	,	9.8%
PIK3CA	,	,	,	6.5%
TP53	30.8%	,	54.9%	,

EGFR mutations predominate in Asian patients, never-smokers, and adenocarcinoma; KRAS mutations are more frequent in Western populations and smokers ^[6]^B2a. ALK rearrangements are enriched in younger patients, who also harbor a higher frequency of other oncogenic alterations ^[42]^B2a. TP53 is the most common mutation overall, particularly in SCC (54.9% Western/SCC) ^[6]^B2a. LKB1 and PTEN mutations occur more often in Western populations and in SCC, respectively ^[6]^B2a. These mutations frequently coexist with driver oncogenes: TP53 mutations are found with KRAS or EGFR in ≥5% of adenocarcinomas, and LKB1 mutations coincide with KRAS or TP53 ^[6]^B2a.

Mutual exclusivity among EGFR, KRAS, and ALK is highly significant in both Western and Asian adenocarcinomas (Pcorr < 0.001) ^[6]^B2a. This exclusivity means that a tumor with one of these drivers rarely harbors another, simplifying diagnostic testing algorithms. Beyond these classic drivers, alterations in STK11 (LKB1) have emerged as a negative predictive biomarker for immunotherapy: dual CTLA-4 plus PD-1/PD-L1 blockade improved OS over single-agent PD-1/PD-L1 inhibition in patients with STK11-mutant tumors (median OS 13.9 versus 7.8 months; HR 0.67) ^[74]^B2a.

Prognostic Gene Expression Signatures

Multiple mRNA expression signatures have been developed to refine prognosis beyond clinical staging. In a meta-analysis of 42 published signatures tested across 15 datasets (1927 patients), 25 remained prognostic after adjusting for clinical factors, and 18 performed significantly better than random signatures ^[61]^B2a. More signatures were validated for adenocarcinoma (17) than for SCC (8), reflecting the greater molecular heterogeneity of adenocarcinoma ^[61]^B2a. These signatures offer the potential to identify high-risk stage I patients who may benefit from adjuvant therapy, but none have yet been incorporated into routine clinical practice.

These histologic and molecular distinctions are not merely academic; they determine sensitivity to targeted therapies, chemotherapy, and immunotherapy, and must be integrated into the diagnostic workup that precedes the clinical presentation described in the next section.

Pearl: When evaluating a new NSCLC biopsy, always request both histologic subtyping and broad molecular profiling (including EGFR, KRAS, ALK, BRAF, and emerging markers like STK11) because the histology itself predicts which mutations are likely and which therapies will be effective, pemetrexed is ineffective in SCC, and datopotamab deruxtecan should be avoided in SCC.

Clinical Presentation

▸Early-stage NSCLC is often asymptomatic; symptoms emerge with central tumor growth or metastatic spread.
▸Dyspnea is a prevalent and disabling symptom in advanced disease; behavioral interventions (breathing techniques, fan therapy) can reduce its severity [85].
▸Leptomeningeal metastases occur in >10% of EGFR-mutated and ALK-rearranged NSCLC; presenting neurological symptoms include headache, nausea, dizziness, and seizures [84].

HY High Yield: In any NSCLC patient with new headache, confusion, or gait disturbance, consider leptomeningeal metastases, especially if the tumor harbors an EGFR mutation or ALK rearrangement. CSF cytology and brain MRI with contrast are essential.

! Warning: Hemoptysis, even if small volume, requires prompt bronchoscopy to exclude central airway tumor. Delayed diagnosis can convert a curable stage to unresectable disease.

The histologic and molecular subtypes detailed above translate into a broad spectrum of clinical presentations that vary by stage, tumor location, and metastatic pattern. Early-stage NSCLC is often asymptomatic, discovered incidentally on imaging performed for other indications. When symptoms do occur, they reflect the intrathoracic tumor burden.

Symptoms

Local tumor effects, central tumors cause cough, hemoptysis, dyspnea, and recurrent post-obstructive pneumonia. Chest wall or pleural invasion produces persistent pleuritic pain. Hoarseness results from recurrent laryngeal nerve involvement, and from mediastinal invasion. Dyspnea is one of the most prevalent and disabling symptoms in advanced disease; a nurse-led behavioral intervention (breathing techniques, postural positions, fan therapy) improved the Modified Medical Research Council Dyspnea Scale score by a mean of -0.33 (95% CI -0.61 to -0.05) ^[85]^A1b.

Metastatic spread, occur in up to 40% of patients with advanced NSCLC and cause headache, focal deficits, seizures, and cognitive changes ^[87]^B2a. Leptomeningeal metastatic disease (LMD), though less common, is increasingly recognized. In a contemporary cohort of over 2000 patients, neurological symptoms, most frequently headache, nausea/vomiting, dizziness, imbalance, blurred vision, lethargy, confusion, and seizures, were present in 64.6% of patients at LMD diagnosis ^[84]^B3b. The cumulative prevalence of LMD exceeds 10% in EGFR-mutated and ALK-rearranged NSCLC ^[84]^B3b. Bone metastases produce pain and pathologic fractures; liver metastases may cause right upper quadrant discomfort.

Systemic symptoms, cancer-related cachexia, defined as ≥5% weight loss within 6 months or BMI <20 kg/m², is common and reduces lean body mass (median increase with anamorelin 0.99 kg in ROMANA 1) ^[92]^A1b. Fatigue, anorexia, and depression further impair quality of life ^[90]^D5.

Signs

Physical examination may reveal, - Decreased breath sounds, dullness to percussion, or pleural effusion

Supraclavicular or scalene lymphadenopathy
Clubbing, Horner syndrome (Pancoast tumor), or hoarseness
Neurologic deficits from brain or

Importantly, sarcopenia, defined on CT using sex-specific skeletal muscle index cutoffs, is present in 28% of patients and is associated with a higher risk of platinum-associated adverse events (grade ≥2 anemia: sHR 1.64, 95% CI 1.17-2.29) ^[79]^B3b. Performance status ( ≥2) is a strong independent prognostic factor in LMD ^[84]^B3b.

Red Flags and Atypical Presentations

Red flags demanding urgent evaluation include hemoptysis, new persistent cough in a smoker aged >50 years, unexplained weight loss >5% over 6 months, and any new neurologic symptom. Atypical presentations include isolated leptomeningeal disease without parenchymal brain metastases (type II LMD per EANO-ESMO criteria), which carries a better survival than type I (positive CSF cytology: median LMOS 16.7 vs 11.2 months) ^[84]^B3b. Up to 21% of LMD cases are diagnosed synchronously with the initial advanced NSCLC diagnosis, underscoring the need for a high index of suspicion ^[84]^B3b.

Pearl: Unexplained neurological symptoms (headache, imbalance, confusion) in a patient with EGFR-mutant or ALK-rearranged NSCLC should prompt urgent brain MRI and consideration of lumbar puncture for CSF cytology, LMD prevalence exceeds 10% in these molecular subtypes, and early detection allows CNS-penetrant TKI therapy that improves survival ^[84]^B3b.

Biopsy and Histologic Diagnosis

▸Adequate tissue acquisition (core needle or surgical biopsy) is critical for both histologic subtyping and molecular biomarker testing.
▸Histologic classification into squamous vs non-squamous NSCLC directly guides therapy selection (e.g., bevacizumab contraindication, pemetrexed efficacy).
▸Immunohistochemistry aids histologic confirmation and can serve as a screening tool for ALK rearrangement, but FISH remains the gold standard.

Dx Diagnostic Essentials: Cytology specimens alone may be insufficient for comprehensive molecular testing; efforts to obtain additional tissue are strongly recommended by ASCO [95].

The clinical features of NSCLC, whether incidentally discovered on imaging or arising from symptoms, mandate histologic confirmation before any treatment decision. The choice of biopsy technique and the adequacy of the specimen directly determine the accuracy of histologic subtyping and the feasibility of downstream molecular testing.

Tissue Acquisition

The goal of biopsy is to obtain sufficient tissue for both histologic classification and biomarker analysis. The ASCO guideline emphasizes that “reasonable efforts to obtain more tissue than what is contained in a routine cytology specimen” are warranted ^[95]^A1c. Core needle biopsy, surgical biopsy, or endobronchial ultrasound-guided sampling typically provide the tissue volume needed. A prospective phase II trial demonstrated that dedicated tumor biopsy for molecular profiling (RRM1 and ERCC1 expression) was feasible in 75 of 85 registered patients (88%) without significant complications ^[102]^C4.

Histologic Classification

NSCLC is broadly divided into squamous cell carcinoma and non-squamous histologies (adenocarcinoma, large-cell carcinoma, and others). This distinction is therapeutically critical: is contraindicated in squamous histology because of the risk of life-threatening hemoptysis ^[95]^A1c, and pemetrexed is preferentially active in non-squamous tumors ^[95]^A1c. The 2nd ESMO Consensus Conference on Lung Cancer confirmed that accurate histologic classification, together with molecular biomarker assessment, is essential for guiding treatment decisions in both early and advanced stages ^[93]^A1c.

Role of Immunohistochemistry

Immunohistochemistry (IHC) is an integral tool for confirming histologic subtype when morphology is ambiguous. For example, TTF-1 and napsin A positivity support adenocarcinoma, while p40 and CK5/6 positivity support squamous cell carcinoma. Although not a substitute for molecular testing, IHC also serves as a screening method for certain biomarkers: the ALK IHC assay, when validated against FISH, may represent “a reliable and cost-effective screening strategy” for ALK rearrangement ^[43]^D5. The ESMO consensus highlights that pathologists should work closely with oncologists to ensure that tissue is triaged for both histologic and molecular analyses ^[93]^A1c.

Adequacy for Molecular Testing

Molecular profiling, including EGFR mutation testing, ALK and ROS1 rearrangements, and PD-L1 expression, requires high-quality tissue. The ASCO guideline supports “reasonable efforts to obtain more tissue” for molecular analysis ^[95]^A1c. For ALK, the Vysis ALK Break Apart FISH Probe Kit is the gold standard, but the assay is “technically challenging and costly”; alternative modalities such as IHC and RT-PCR are being explored ^[43]^D5. In the FLEX study, biomarker analysis (KRAS, EGFR mutations, EGFR copy number, PTEN expression) was successfully performed on formalin-fixed paraffin-embedded tumor tissue from 395 to 436 patients, demonstrating that archival tissue can be used for retrospective molecular correlation ^[53]^B2b. Similarly, the SAVANNAH study required MET IHC and FISH to define MET overexpression and amplification ^[96]^B2b. The key clinical point is that the initial biopsy must be planned with these downstream tests in mind; a small cytology specimen may be inadequate.

Pearl: The biopsy must be planned from the outset to provide both histologic classification and enough material for molecular testing, a core needle or surgical biopsy is preferable to cytology alone, as inadequate tissue precludes the targeted therapies that drive modern NSCLC management ^[95]^A1c^[102]^C4.

Imaging

▸After negative systematic endosonography, confirmatory mediastinoscopy can be omitted in patients with resectable NSCLC (unforeseen N2 rate 8.8% vs 7.7%, noninferior).
▸PET-based radiotherapy target volume reduction is noninferior to conventional elective nodal irradiation and may improve locoregional control (1-year progression 14% vs 29%).
▸CT-based surveillance after resection detects more recurrences and second primary lung cancers than x-ray alone, but does not improve overall survival.

HY High Yield: After a negative systematic endosonography (EBUS), confirmatory mediastinoscopy can be omitted; the unforeseen N2 rate is approximately 8% and does not compromise survival [18].

After histologic confirmation, imaging defines the anatomic extent of disease and guides the selection of curative versus palliative management. Modality choice and sequencing follow established guideline recommendations, with the goal of detecting mediastinal involvement, distant metastases, and second primary cancers that change treatment strategy.

Imaging for Staging

Initial staging begins with a contrast-enhanced CT chest extending through the liver and adrenals. 18F-FDG PET/CT is recommended for all patients with suspected stage I-III disease; it detects occult distant metastases in approximately 10-15% of patients and refines the radiotherapy target volume. Brain MRI (or contrast CT if MRI is contraindicated) is indicated for stage II-III disease and for any patient with neurologic symptoms, given the 20-30% prevalence of at diagnosis in advanced stages.

Mediastinal nodal staging requires tissue confirmation when imaging is suspicious. The first-line invasive modality is endobronchial ultrasound (EBUS) or endoscopic ultrasound (EUS). After a negative systematic endosonography, confirmatory mediastinoscopy can be omitted: in a randomized noninferiority trial, the unforeseen N2 rate was 8.8% after immediate resection versus 7.7% after mediastinoscopy first, meeting the noninferiority margin (Δ 1.03%, upper 95% CI limit 7.2%; Pnoninferior = 0.0144) ^[18]^A1b. For patients with clinical stage I NSCLC who are candidates for ( ), PET/CT alone is sufficient; there is no evidence that more invasive lymph node staging improves outcomes when PET/CT shows no nodal involvement ^[32]^B2a.

PET for Radiotherapy Planning

PET-based target volume delineation improves the therapeutic ratio for chemoradiotherapy. The PET-Plan trial randomly assigned patients with locally advanced NSCLC to conventional target volumes (including elective nodal irradiation) or volumes defined by 18F-FDG PET alone. In the per-protocol analysis, the 1-year locoregional progression rate was 14% (95% CI 5-21) with PET-based planning versus 29% (95% CI 17-38) with conventional planning (HR 0.57, 95% CI 0.30-1.06), meeting noninferiority and suggesting improved local control ^[124]^A1b. Toxicity was similar between arms. Hypoxia PET imaging (e.g., with [18F]FMISO or [18F]FAZA) can detect radioresistant tumor subvolumes; although still investigational, it may guide dose-escalation strategies ^[120]^B2a.

Surveillance Imaging

After curative-intent resection, surveillance imaging aims to detect recurrent disease and second primary lung cancers (SPLCs). The IFCT-0302 trial compared CT-based follow-up (chest x-ray plus thoracoabdominal CT and bronchoscopy for non-adenocarcinoma) with minimal follow-up (x-ray and clinic visits) in patients with completely resected stage I-IIIA NSCLC. The median overall survival was 10.3 years with CT-based follow-up versus 8.5 years with minimal follow-up, a difference that did not reach statistical significance (adjusted HR 0.95, 95% CI 0.83-1.10; P = 0.49) ^[123]^A1b. However, CT detected more recurrences (32.6% vs 27.7%) and more SPLCs (4.5% vs 3.0%), enabling earlier curative-intent treatment for the latter. The protocol schedule was every 6 months for the first 2 years, then yearly through 5 years ^[123]^A1b.

The risk of SPLC is substantial: in the CALGB 140503 trial, the rate per patient per year was 3.4% (95% CI 2.9-4.1), and the 5-year cumulative incidence was 15.9% (95% CI 12.9-18.9) ^[117]^A1b. These data support continued CT surveillance, particularly in countries where is already implemented.

Brain Imaging in Advanced Disease

For patients with advanced or metastatic NSCLC, brain MRI is essential at baseline and during therapy. In the ALEX trial, which enrolled ALK-positive patients, routine brain imaging every 8 weeks revealed that alectinib achieved a CNS objective response rate of 78.6% in patients without prior radiotherapy, versus 40.0% with crizotinib, and significantly delayed CNS progression (P < 0.0001) ^[115]^A1b. Among patients treated with crizotinib in the PROFILE series, 31% had asymptomatic brain metastases at baseline; the intracranial disease control rate at 12 weeks was 56% in previously untreated patients, and the median intracranial time to progression was 7 months (95% CI 6.7-16.4) ^[119]^A1b. Progression of preexisting or development of new brain lesions is common with crizotinib, underscoring the need for serial brain imaging and CNS-penetrant agents.

Pearl: After negative systematic endosonography, confirmatory mediastinoscopy can be safely omitted; the risk of unforeseen N2 is approximately 8% and does not compromise survival. For surveillance, CT-based follow-up detects more recurrences and second primary lung cancers, though without a proven overall survival benefit.

Imaging for Staging

Modality	Indication	Key Evidence
Contrast-enhanced CT chest	Initial staging, tumor size, and mediastinal involvement	NCCN/ESMO guidelines ^[111]^A1c^[93]^A1c
18F-FDG PET/CT	Distant metastases, radiotherapy planning	PET-Plan trial ^[124]^A1b
Brain MRI	Stage II-III or neurologic symptoms	ALEX ^[115]^A1b, PROFILE ^[119]^A1b
EBUS/EUS	Mediastinal nodal staging	MEDIASTrial ^[18]^A1b
Mediastinoscopy	After negative EBUS (can be omitted)	MEDIASTrial ^[18]^A1b

Surveillance After Curative Resection

Schedule	Modality	Evidence
Every 6 months for 2 years, then yearly to 5 years	Chest CT (or x-ray + CT)	IFCT-0302 ^[123]^A1b
Annual CT thereafter	Consider for high-risk patients	CALGB 140503 ^[117]^A1b

Molecular Diagnostics and Biomarkers

▸NCCN/ASCO/ESMO guidelines mandate testing for at least EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK, HER2, KRAS G12C, and PD-L1 in advanced NSCLC.
▸Turnaround time >2 weeks for EGFR/ALK testing doubles the risk of early nontargeted therapy and worsens PFS.
▸Liquid biopsy (plasma ctDNA) is a complementary tool for detection of driver mutations and resistance mechanisms when tissue is limited.

Imaging delineates the extent of disease, but molecular testing defines its biology. For patients with advanced non-small cell lung cancer (NSCLC), identifying driver genomic alterations and immune biomarkers has become a prerequisite for optimal first-line therapy. The NCCN guidelines recommend testing for at least EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2, KRAS G12C, and PD-L1 expression in all patients with advanced non-squamous NSCLC, and should be considered in squamous cell carcinoma in never-smokers or when clinical features suggest a driver mutation ^[76]^A1c^[78]^A1c^[129]^A1c^[130]^A1c.

Indications and Recommendations

Molecular testing is indicated at diagnosis for any patient with stage IV or recurrent NSCLC who is a candidate for systemic therapy. For earlier stages, testing is increasingly performed at resection to guide adjuvant targeted therapy decisions. The ESMO and ASCO guidelines align with NCCN in recommending comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) as the preferred approach because it conserves tissue and captures all actionable alterations in a single assay ^[76]^A1c^[78]^A1c. Single-gene testing (PCR, FISH, IHC) remains acceptable when NGS is unavailable or tissue is limited, but sequential single-gene testing can delay results and deplete biopsy material.

Testing Modalities and Turnaround Time

NGS-based panels can detect mutations, fusions, and copy-number alterations simultaneously. PD-L1 immunohistochemistry (IHC) is performed separately using validated assays (22C3, 28-8, SP142, SP263) to determine eligibility for immune checkpoint inhibitors. Real-world data from a large US cohort (2011-2023) show that NGS use increased over time, but the mean turnaround time (TAT) plateaued at approximately 3 weeks. Fewer than half of patients with ALK/EGFR-altered NSCLC had a TAT of ≤2 weeks, and 1 in 8 initiated early nontargeted therapy. Longer TAT was associated with early nontargeted treatment (odds ratio 1.83 per week; TAT >2 vs ≤2 weeks odds ratio 6.02) and worse median progression-free survival (9 vs 11 months) ^[140]^B3b. Guidelines recommend a 2-week TAT for EGFR and ALK testing to avoid suboptimal first-line treatment ^[76]^A1c^[140]^B3b.

Key Actionable Biomarkers

Biomarker	Prevalence in NSCLC	Testing Method	Targeted Therapy Implication
EGFR (ex19del, L858R, T790M)	~15% (higher in Asian, never-smokers)	NGS, PCR, cfDNA	First-line osimertinib; amivantamab-lazertinib improves PFS over osimertinib in high-risk subgroups (TP53 co-mutation, detectable ctDNA) ^[132]^A1b
ALK rearrangements	3-7%	NGS, FISH, IHC	Lorlatinib shows higher ORR (62% vs 32% by plasma) in patients with ALK mutations after second-generation TKIs ^[138]^B2b
ROS1 rearrangements	1-2%	NGS, FISH	Entrectinib, crizotinib, etc.
BRAF V600E	1-2%	NGS, PCR	Dabrafenib + trametinib
MET exon 14 skipping	3%	NGS	Capmatinib, tepotinib
RET rearrangements	1-2%	NGS, FISH	Selpercatinib, pralsetinib
NTRK fusions	<1%	NGS, IHC	Larotrectinib, entrectinib
HER2 mutations	2-4%	NGS	deruxtecan (T-DXd) 5.4 mg/kg: ORR 49% (95% CI 39.0-59.1) in DESTINY-Lung02 ^[135]^B2b
HER2 overexpression (IHC 3+/2+)	~20-30% (IHC 3+ ~5%)	IHC	T-DXd 5.4 mg/kg: ORR 34.1% (95% CI 20.1-50.6) in DESTINY-Lung01 ^[106]^B2b
KRAS G12C	~13% (more common in smokers)	NGS, PCR	Sotorasib, adagrasib; STK11 co-mutation predicts worse outcome but may benefit from dual CTLA-4 + PD-L1/PD-1 blockade (HR 0.67, 95% CI 0.49-0.91) ^[74]^B2a
PD-L1 TPS	Variable	IHC (22C3, etc.)	Guides immunotherapy; TPS ≥50% monotherapy, ≥1% combinations; TPS <1% may benefit from dual CTLA-4 + PD-L1/PD-1 (5-year OS 16.6% vs 9.3%) ^[74]^B2a
STK11/LKB1 mutations	~15-30% (often co-occur with KRAS)	NGS	Associated with primary resistance to PD-1 monotherapy; dual checkpoint improves OS ^[74]^B2a

Beyond these, ERCC1 expression by IHC identified patients most likely to benefit from adjuvant -based chemotherapy: ERCC1-negative tumors had prolonged survival with chemotherapy (HR 0.65, 95% CI 0.50-0.86), while ERCC1-positive tumors derived no benefit ^[136]^A1b. Although not routinely used in current practice, this highlights the potential for chemotherapy-predictive biomarkers.

Liquid Biopsy

Circulating tumor DNA (ctDNA) from plasma provides a noninvasive alternative when tissue is insufficient or to capture tumor heterogeneity. Detection of EGFR mutations in cfDNA using peptide nucleic acid-mediated PCR is feasible; the L858R mutation in cfDNA is a poor prognostic marker (OS 13.7 vs 30.0 months; HR 2.70, 95% CI 1.60-4.56) ^[139]^A1b. Urinary cell-free DNA (ucfDNA) has been investigated: pooled sensitivity 0.80 (95% CI 0.75-0.85) and specificity 0.96 (95% CI 0.88-0.98) for non-urothelial cancers, with mutation-based assays outperforming methylation-based approaches ^[86]^B2a. Liquid biopsy also enables monitoring for acquired resistance mechanisms, such as EGFR T790M after first- or second-generation TKIs, and detection of ALK resistance mutations that predict lorlatinib response ^[138]^B2b.

Novel Biomarkers Under Evaluation

Emerging actionable targets include HER3 (broadly expressed in NSCLC) - patritumab deruxtecan (HER3-DXd) showed a confirmed ORR of 41.0% (95% CI 30.0-52.7%) and median OS of 16.2 months (95% CI 11.2-21.9 months) in EGFR-mutant NSCLC after TKI and platinum-based chemotherapy ^[141]^C4. The bispecific antibody-drug conjugate izalontamab brengitecan (Iza-bren) targeting EGFR and HER3 demonstrated a cORR of 47.4% (95% CI 39.7-55.1%) and median OS 24.8 months in heavily pretreated EGFR-mutant NSCLC ^[131]^A1a. These agents underscore the expanding landscape of biomarker-directed therapies.

Pearl: In advanced NSCLC, comprehensive NGS-based molecular testing with a TAT of ≤2 weeks is critical; every week of delay increases the odds of initiating suboptimal nontargeted therapy by 83% (OR 1.83), and a TAT beyond 2 weeks multiplies that risk more than sixfold (OR 6.02). Prioritize testing for EGFR, ALK, ROS1, BRAF V600E, METex14, RET, NTRK, HER2, KRAS G12C, and PD-L1 at diagnosis.

Recommended Actionable Biomarkers in Advanced NSCLC

Biomarker	Prevalence	Testing Methods	Targeted Therapy Implication
EGFR (ex19del, L858R, T790M)	~15%	NGS, PCR, cfDNA	First-line osimertinib; amivantamab-lazertinib in high-risk subgroups ^[132]^A1b
ALK rearrangements	3-7%	NGS, FISH, IHC	Lorlatinib after second-generation TKIs; ALK mutations predict response ^[138]^B2b
ROS1 rearrangements	1-2%	NGS, FISH	Crizotinib, entrectinib
BRAF V600E	1-2%	NGS, PCR	Dabrafenib + trametinib
MET exon14 skipping	3%	NGS	Capmatinib, tepotinib
RET rearrangements	1-2%	NGS, FISH	Selpercatinib, pralsetinib
NTRK fusions	<1%	NGS, IHC	Larotrectinib, entrectinib
HER2 mutations	2-4%	NGS	T-DXd 5.4 mg/kg: ORR 49% ^[135]^B2b
HER2 overexpression	~5% IHC 3+	IHC	T-DXd 5.4 mg/kg: ORR 34.1% ^[106]^B2b
KRAS G12C	~13%	NGS, PCR	Sotorasib, adagrasib; STK11 co-mutation benefits from dual checkpoint ^[74]^B2a
PD-L1 TPS	Variable	IHC (22C3, etc.)	Guides immunotherapy; TPS <1% may benefit from dual CTLA-4 + PD-L1/PD-1 ^[74]^B2a
STK11/LKB1	15-30%	NGS	Resistance to PD-1 monotherapy; improved OS with dual checkpoint ^[74]^B2a

Staging

▸Staging uses the AJCC/UICC 8th edition TNM classification, with refined T size cutoffs and reclassification of additional nodules.
▸Stage I-IIIA disease is generally considered potentially resectable; stage IIIB-IV is managed with definitive chemoradiation or systemic therapy.
▸Stage grouping directly determines the role of adjuvant therapy, chemoradiotherapy, and the use of targeted/immunotherapy agents.

HY High Yield: The 8th edition T size cutoffs (T1 ≤3 cm, T2 3-5 cm, T3 5-7 cm, T4 >7 cm) are essential for accurate staging; misclassification can alter stage grouping and treatment recommendations.

While molecular profiling identifies targetable drivers, the anatomic extent of disease, determined by staging, dictates the initial treatment modality and prognosis. The current standard is the American Joint Committee on Cancer ( )/Union for International Cancer Control (UICC) staging system, 8th edition, which incorporates tumor size, nodal involvement, and metastasis status to assign a stage group from I to IV ^[149]^A1b. The 8th edition refined T descriptors with specific size cutoffs (T1 ≤3 cm, T2 3-5 cm, T3 5-7 cm, T4 >7 cm) and reclassified T3 and T4 tumors based on additional nodules, improving prognostic discrimination.

TNM Stage Groupings (8th Edition)

The table below summarizes the stage groupings and their corresponding TNM combinations. Accurate staging requires integration of clinical, radiographic, and pathologic data, including , , and with or .

Stage Group	TNM Combination	Description
IA1	T1a N0 M0	Tumor ≤1 cm, no nodal or distant spread
IA2	T1b N0 M0	Tumor >1-2 cm, no nodal or distant spread
IA3	T1c N0 M0	Tumor >2-3 cm, no nodal or distant spread
IB	T2a N0 M0	Tumor >3-4 cm, no nodal or distant spread
IIA	T2b N0 M0	Tumor >4-5 cm, no nodal or distant spread
IIB	T1-T2 N1 M0; T3 N0 M0	Tumor ≤5 cm with ipsilateral hilar node involvement, or tumor 5-7 cm without nodal spread
IIIA	T1-T2 N2 M0; T3 N1 M0; T4 N0-N1 M0	Tumor up to 7 cm with ipsilateral mediastinal node involvement, or larger tumor (≥7 cm) with hilar or mediastinal nodes
IIIB	T1-T2 N3 M0; T3-T4 N2 M0	Tumor of any size with contralateral mediastinal/supraclavicular nodes, or larger tumor with mediastinal nodes
IIIC	T3-T4 N3 M0	Tumor >5 cm with contralateral mediastinal/supraclavicular nodes
IV	Any T, Any N, M1	Distant metastasis

Clinical Implications by Stage Group

Stage I (IA1-IB): Disease is confined to the lung without nodal involvement. Surgical resection, typically with mediastinal lymph node dissection, is the primary treatment. Adjuvant chemotherapy is not recommended for stage IA and is considered for selected IB tumors with high-risk features (e.g., visceral pleural invasion, vascular invasion) ^[113]^A1c.
Stage II (IIA-IIB): Involves either hilar nodes (N1) or a larger primary tumor (T3). Complete surgical resection followed by platinum-based adjuvant chemotherapy is standard, improving 5-year survival by approximately 5-15% ^[113]^A1c. For stage II-IIIA -mutated NSCLC, adjuvant for 3 years provides a disease-free survival benefit (HR 0.23, 95% CI 0.18-0.30) ^[145]^A1b.
Stage IIIA: A heterogeneous group that includes tumors with ipsilateral mediastinal node involvement (N2) or T3-T4 tumors with hilar nodes. Stage IIIA is considered potentially resectable in selected patients, particularly those with single-station N2 disease. Neoadjuvant or induction chemotherapy may be used ^[12]^B2b. For patients with unresectable stage IIIA, definitive concurrent (CRT) is the standard, with a 5-year survival benefit of 4.5% over sequential CRT (HR 0.84, 95% CI 0.74-0.95) ^[144]^A1a. Consolidation for 12 months in patients without progression after CRT improves 5-year overall survival (42.9% vs 33.4%) ^[149]^A1b.
Stage IIIB-IIIC: Unresectable disease; definitive concurrent CRT with or without consolidation durvalumab is the standard of care ^[148]^A1b. The PACIFIC regimen (CRT followed by durvalumab) remains the reference, with a 5-year PFS rate of 33.1% vs 19.0% (HR 0.52, 95% CI 0.42-0.65) ^[149]^A1b.
Stage IV: Metastatic disease; management is systemic therapy (chemotherapy, targeted therapy, or immunotherapy) based on molecular biomarkers and PD-L1 expression. For patients with PD-L1 tumor proportion score ≥50%, monotherapy improves median OS (30.0 vs 14.2 months; HR 0.63, 95% CI 0.47-0.86) ^[146]^A1b. For those with driver alterations, targeted agents such as for EGFR-mutated disease are indicated ^[142]^A1c.

Accurate stage assignment is critical because it determines whether the goal of treatment is curative (resection or definitive CRT) or palliative (systemic therapy). The next section, Management Overview, translates these stage groupings into integrated treatment algorithms.

Pearl: The 8th edition T size cutoffs (T1 ≤3 cm, T2 3-5 cm, T3 5-7 cm, T4 >7 cm) are essential for accurate staging; misclassification can alter stage grouping and treatment recommendations, always verify the TNM combination before assigning the final stage.

Management Overview

▸Management is stratified by stage, performance status, and biomarkers (EGFR, ALK, PD-L1).
▸For stage III unresectable NSCLC, concurrent chemoradiotherapy followed by durvalumab provides 5-year OS of 42.9%.
▸In advanced ALK-positive NSCLC, lorlatinib achieved 5-year PFS of 60% and intracranial control with HR 0.06.

HY High Yield: Before starting treatment for advanced NSCLC, confirm that NGS results (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK) and PD-L1 IHC are available, missing a targetable alteration can deny a patient a therapy with 5-year PFS >60% [159].

Once staging is complete, management is determined by stage, performance status (PS), and the molecular profile of the tumor. The NCCN Clinical Practice Guidelines in Oncology for NSCLC provide the framework for treatment decisions, updated annually based on FDA approvals and clinical data ^[76]^A1c^[154]^A1c. A multidisciplinary discussion, including thoracic surgery, radiation oncology, medical oncology, and pulmonology, is recommended before initiating any therapy ^[128]^A1c.

Risk Stratification and Initial Assessment

Before selecting a treatment modality, the clinician must assess:

Performance status: 0-2 generally qualifies for active treatment; PS 3-4 may be candidates for palliative care or single-agent therapy ^[128]^A1c.
TNM stage: Stage I-IIIA (resectable), stage IIIB-IIIC (unresectable locally advanced), and stage IV (metastatic) each follow distinct algorithms ^[76]^A1c.
Molecular testing: For advanced non-squamous NSCLC, tumor NGS is recommended by ESMO to detect actionable alterations in EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, and others ^[156]^A1c. Squamous histology is also tested if the patient is a never-smoker or has a small biopsy ^[40]^A1c.
PD-L1 expression: Programmed death-ligand 1 immunohistochemistry (IHC) guides immunotherapy decisions across all stages ^[76]^A1c.

Early-Stage NSCLC (Stage I-IIIA)

Surgical resection is the cornerstone for operable tumors. Decisions about adjuvant therapy depend on stage and molecular findings.

Adjuvant osimertinib after complete resection of stage IB-IIIA EGFR-mutant (exon 19 deletion or L858R) NSCLC prolongs disease-free survival (DFS) versus placebo (HR 0.23; 95% CI 0.18-0.30 for stage II-IIIA; 4-year DFS rate 70% vs 29%). CNS DFS is also improved (HR 0.24; 95% CI 0.14-0.42) ^[145]^A1b.
Adjuvant after platinum-based chemotherapy in resected stage II-IIIA NSCLC with PD-L1 tumor cell (TC) ≥50% shows an overall survival trend (HR 0.43; 95% CI 0.24-0.78) ^[114]^A1b.
For patients who are not surgical candidates, stereotactic ablative radiotherapy ( ) is an alternative ^[76]^A1c.

Locally Advanced NSCLC (Stage III)

For unresectable stage III disease, the standard is concurrent chemoradiotherapy, followed by consolidation .

A meta-analysis of six randomized trials (1,205 patients) demonstrated that concomitant radiochemotherapy improves overall survival compared with sequential therapy (HR 0.84; 95% CI 0.74-0.95), with an absolute benefit of 5.7% at 3 years (from 18.1% to 23.8%) and 4.5% at 5 years. However, grade 3-4 acute esophageal toxicity increased from 4% to 18% (relative risk 4.9; 95% CI 3.1-7.8) ^[144]^A1a.
After concurrent chemoradiotherapy, durvalumab 10 mg/kg every 2 weeks for 12 months improves 5-year overall survival (42.9% vs 33.4%; stratified HR 0.72; 95% CI 0.59-0.89) and 5-year progression-free survival (33.1% vs 19.0%; HR 0.55; 95% CI 0.45-0.68) ^[161]^A1b.

Advanced or Metastatic NSCLC (Stage IV)

Systemic therapy is the mainstay, with the choice driven by biomarkers and histology.

First-Line Therapy

EGFR-mutant disease: Amivantamab-lazertinib versus osimertinib in the MARIPOSA trial prolonged progression-free survival (PFS) overall (HR 0.70; P < 0.001), including in high-risk subgroups such as TP53 co-mutations (HR 0.65; 95% CI 0.48-0.87), baseline liver metastases (HR 0.58; 95% CI 0.37-0.91), and detectable baseline ctDNA (HR 0.68; 95% CI 0.53-0.86) ^[132]^A1b. Osimertinib remains a standard option based on prior approvals ^[76]^A1c.
ALK-positive disease: Lorlatinib 100 mg once daily in the CROWN study achieved a median PFS that has not been reached after 5 years of follow-up, with a 5-year PFS rate of 60% (95% CI 51-68) vs 8% with crizotinib (HR 0.19; 95% CI 0.13-0.27). Intracranial efficacy was sustained (HR 0.06; 95% CI 0.03-0.12) ^[159]^A1b. Alectinib 600 mg twice daily also shows superior PFS over crizotinib (median 34.8 vs 10.9 months; HR 0.43; 95% CI 0.32-0.58) with a 5-year OS rate of 62.5% vs 45.5% ^[157]^A1b.
Squamous NSCLC (any PD-L1): 200 mg plus and / improves OS vs chemotherapy alone (HR 0.71; 95% CI 0.59-0.85), with 5-year OS rates of 18.4% vs 9.7% ^[160]^A1b.
Subcutaneous alternatives: Pembrolizumab 790 mg subcutaneously every 6 weeks is noninferior to intravenous 400 mg every 6 weeks in terms of drug exposure and efficacy when combined with chemotherapy (ORR 45.4% vs 42.1%) ^[158]^A1b. Atezolizumab 1875 mg subcutaneously every 3 weeks is also noninferior to intravenous 1200 mg (PFS HR 1.08; 95% CI 0.82-1.41) ^[8]^A1b.

Post-EGFR TKI Therapy

For patients who progress on EGFR-TKIs, a network meta-analysis of 9 RCTs (2,534 patients) recommends platinum-based chemotherapy combined with an anti-PD-1/PD-L1 agent plus an anti-VEGF agent (or a bispecific antibody) or with amivantamab. Both combinations significantly prolong PFS vs chemotherapy alone (HR 0.51 and 0.48, respectively) and improve objective response rate (ORR) ^[2]^A1a.

Special Considerations:

According to the ASCO-SNO-ASTRO guideline, surgery is reasonable for large, symptomatic tumors with mass effect. For 1-4 asymptomatic unresected brain metastases, ( ) alone should be offered. Whole-brain radiotherapy with memantine and hippocampal avoidance is an option for patients with ≥4 lesions and expected survival ≥4 months. Local therapy should not be deferred for asymptomatic brain metastases unless specifically recommended after multidisciplinary discussion ^[21]^A1a.

Pearl: For advanced NSCLC, always obtain tumor NGS and PD-L1 IHC before starting first-line therapy, the choice of targeted therapy (lorlatinib for ALK, amivantamab-lazertinib or osimertinib for EGFR) or immunotherapy-chemotherapy doublet depends on results that can change the 5-year survival trajectory by 30- ^[159]^A1b^[145]^A1b^[160]^A1b.

These treatment paradigms are detailed in dedicated pages on surgical management, radiation therapy, systemic therapy, and palliative care, which discuss modality-specific protocols, dosing schedules, toxicity management, and surveillance.

Pivotal Trials Guiding First-Line Therapy in Advanced NSCLC

Biomarker	Preferred Regimen	Key Efficacy (vs Comparator)	Reference
EGFR exon 19 del / L858R	Amivantamab + lazertinib	PFS HR 0.70; P<0.001; TP53 co-mutation HR 0.65	^[132]^A1b
ALK rearrangement	Lorlatinib 100 mg once daily	5-year PFS 60% vs 8%; HR 0.19; intracranial HR 0.06	^[159]^A1b
ALK rearrangement	Alectinib 600 mg twice daily	Median PFS 34.8 vs 10.9 mo; HR 0.43; 5-year OS 62.5% vs 45.5%	^[157]^A1b
Squamous, any PD-L1	Pembrolizumab + carboplatin + (nab-)paclitaxel	OS HR 0.71; 5-year OS 18.4% vs 9.7%	^[160]^A1b

History and Evolution of Treatment

▸Treatment of advanced NSCLC has evolved from platinum‑based chemotherapy to biomarker‑guided targeted therapy and immunotherapy, driven by landmark randomized trials.
▸The ALEX trial established alectinib as the standard first‑line ALK inhibitor, with a median OS of 81.1 months versus 54.2 months for crizotinib (HR 0.78) [165].
▸KEYNOTE‑189 demonstrated that pembrolizumab plus pemetrexed‑platinum significantly improves OS (HR 0.56) and PFS (HR 0.49) in metastatic nonsquamous NSCLC, regardless of PD‑L1 expression [164].
▸IMpower010 showed adjuvant atezolizumab improves OS in PD‑L1 ≥50% stage II-IIIA NSCLC (HR 0.43) [114].
▸Subcutaneous formulations of pembrolizumab and atezolizumab have been shown to be noninferior to intravenous administration, offering an alternative with reduced infusion time [8,158].

HY High Yield: The evolution of NSCLC treatment is best understood as three overlapping revolutions: chemotherapy (1990s-2000s), targeted therapy (2005-present), and immunotherapy (2015-present). The ALEX trial's final OS analysis (HR 0.78) and KEYNOTE‑189's OS benefit (HR 0.56) are the most practice‑changing data from each era.

From the management overview, the treatment of advanced NSCLC has transformed over two decades from a one-size-fits-all chemotherapy approach to a biomarker-driven, immunotherapy-enriched paradigm. The systematic introduction of molecularly targeted therapies and immune checkpoint inhibitors, each supported by pivotal randomized trials, has progressively displaced older regimens and established new standards of care.

The Chemotherapy Era

Through the early 2000s, platinum-based doublets ( or combined with a third-generation agent such as pemetrexed, , or a taxane) were the sole first-line option for advanced NSCLC, yielding median overall survival (OS) of approximately 8-10 months. The 2012 NCCN Guidelines reflected this paradigm, focusing on systemic therapy for stage IV disease without reference to biomarker selection ^[128]^A1c. Choice of agent was histology-driven: pemetrexed was reserved for nonsquamous histology, and was added for eligible nonsquamous patients. Single-agent chemotherapy and non-platinum doublets, once used empirically, were abandoned because of inferior efficacy and greater toxicity.

The Targeted Therapy Revolution

The identification of sensitizing epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements as actionable driver alterations fundamentally changed the therapeutic landscape. The 2015 NCCN Guidelines emphasized that appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations, mandating testing of tumor tissue ^[40]^A1c. Gefitinib and erlotinib became first-line standards for EGFR-mutant disease, and crizotinib for ALK-positive NSCLC. The ALEX trial established alectinib as the preferred ALK inhibitor: alectinib 600 mg twice daily significantly prolonged investigator-assessed progression-free survival (PFS) versus crizotinib (median PFS 34.8 versus 10.9 months; HR 0.43, 95% CI 0.32-0.58) ^[157]^A1b. Final OS analysis after a median follow-up of 53.5 months confirmed a median OS of 81.1 versus 54.2 months (HR 0.78, 95% CI 0.56-1.08) and a 5-year OS rate of 62.5% (95% CI 54.3-70.8) for alectinib versus 45.5% for crizotinib, with a median duration of response of 42.3 versus 11.1 months (HR 0.41, 95% CI 0.30-0.56) ^[165]^A1b. These data cemented alectinib as a standard of care for first-line ALK-positive NSCLC ^[165]^A1b. For EGFR-mutant disease, the MARIPOSA trial demonstrated that the combination of amivantamab plus lazertinib significantly improved PFS compared with osimertinib (HR 0.70; P < 0.001), with particular benefit in patients with TP53 co-mutations (HR 0.65, 95% CI 0.48-0.87) or baseline liver metastases (HR 0.58, 95% CI 0.37-0.91) ^[132]^A1b. The 2026 NCCN Guidelines now list multiple targeted therapy options for advanced NSCLC with actionable biomarkers, reflecting the rapid expansion of druggable targets ^[78]^A1c.

The Immunotherapy Era

The programmed death-1 (PD-1) checkpoint inhibitors and , and the PD-L1 inhibitor , entered the advanced NSCLC arena in the mid-2010s. KEYNOTE-189, a landmark phase III trial, evaluated pembrolizumab 200 mg every 3 weeks plus pemetrexed-platinum versus placebo plus chemotherapy in previously untreated metastatic nonsquamous NSCLC. After a median follow-up of 31.0 months, the combination improved OS (HR 0.56, 95% CI 0.46-0.69) and PFS (HR 0.49, 95% CI 0.41-0.59) regardless of PD-L1 expression, with an objective response rate of 48.3% versus 19.9% ^[164]^A1b. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus chemotherapy versus 66.8% of controls ^[164]^A1b. In the adjuvant setting, IMpower010 demonstrated that atezolizumab after platinum-based chemotherapy significantly improved disease-free survival in PD-L1-positive stage II-IIIA NSCLC. The first OS interim analysis showed a stratified HR of 0.995 (95% CI 0.78-1.28) in the intention-to-treat population, but in the stage II-IIIA PD-L1 tumor cell ≥50% subgroup, the OS HR was 0.43 (95% CI 0.24-0.78) ^[114]^A1b. These findings support atezolizumab as an adjuvant option for high-risk PD-L1-positive patients ^[114]^A1b.

Recent Innovations: Subcutaneous Formulations and Combination Strategies

To improve convenience and reduce infusion burden, subcutaneous versions of checkpoint inhibitors have been developed. The phase III 3475A-D77 trial showed that subcutaneous pembrolizumab 790 mg every 6 weeks was noninferior to intravenous pembrolizumab 400 mg every 6 weeks in combination with chemotherapy, with a geometric mean ratio (GMR) for cycle 1 AUC of 1.14 (96% CI 1.06-1.22) and an objective response rate of 45.4% versus 42.1% (ORR ratio 1.08, 95% CI 0.85-1.37) ^[158]^A1b. Similarly, IMscin001 Part 2 demonstrated that subcutaneous atezolizumab 1875 mg every 3 weeks had noninferior drug exposure compared with intravenous atezolizumab 1200 mg (cycle 1 Ctrough GMR 1.05, 90% CI 0.88-1.24), with similar efficacy (PFS HR 1.08, 95% CI 0.82-1.41) and safety ^[8]^A1b. These data support subcutaneous administration as an alternative for patients who prefer it.

What Was Abandoned and Why

Non-platinum doublets, single-agent chemotherapy, and empirical use of targeted agents without biomarker selection were abandoned because of inferior outcomes and toxicity. The 2013 NCCN Guidelines emphasized diagnostic evaluation of suspected lung cancer to avoid futile treatment ^[155]^A1c. The 2018 update added a dedicated biomarker section, codifying the principle that treatment selection must be guided by molecular testing and PD-L1 expression ^[130]^A1c. The evolution of the NCCN Guidelines from 2012 to 2026 mirrors the field’s transition from histology-based chemotherapy to precision medicine and immunotherapy ^[78]^A1c^[128]^A1c.

Pearl: The treatment of NSCLC has evolved from a one-size-fits-all chemotherapy approach to a highly personalized strategy based on molecular biomarkers and immune checkpoint expression, with landmark trials demonstrating significant survival improvements, alectinib more than doubled median OS in ALK-positive NSCLC (81.1 vs 54.2 months, HR 0.78) ^[165]^A1b, and pembrolizumab plus chemotherapy reduced the risk of death by in metastatic nonsquamous NSCLC (HR 0.56) ^[164]^A1b.

Landmark Trials in the Evolution of NSCLC Treatment

Trial	Regimen	Patient Population	Key Efficacy Outcome	Reference
ALEX	Alectinib 600 mg BID vs crizotinib 250 mg BID	First‑line ALK‑positive advanced NSCLC	Median OS 81.1 vs 54.2 months (HR 0.78, 95% CI 0.56-1.08); 5‑year OS rate 62.5% vs 45.5%	^[165]^A1b
KEYNOTE‑189	Pembrolizumab 200 mg + pemetrexed‑platinum vs placebo + chemo	First‑line metastatic nonsquamous NSCLC	OS HR 0.56 (95% CI 0.46-0.69); PFS HR 0.49 (95% CI 0.41-0.59); ORR 48.3% vs 19.9%	^[164]^A1b
IMpower010	Atezolizumab 1200 mg q3w vs BSC after platinum‑based chemo	Adjuvant stage II-IIIA NSCLC	OS HR 0.43 (95% CI 0.24-0.78) in PD‑L1 TC ≥50% subgroup	^[114]^A1b
MARIPOSA	Amivantamab + lazertinib vs osimertinib	First‑line EGFR‑mutant advanced NSCLC	PFS HR 0.70 (P < 0.001); in TP53 co‑mutations HR 0.65 (95% CI 0.48-0.87)	^[132]^A1b
3475A‑D77	Pembrolizumab SC 790 mg q6w vs IV 400 mg q6w + chemo	First‑line metastatic NSCLC	ORR 45.4% vs 42.1% (ORR ratio 1.08, 95% CI 0.85-1.37); noninferior exposure	^[158]^A1b
IMscin001	Atezolizumab SC 1875 mg q3w vs IV 1200 mg	Previously treated advanced NSCLC	PFS HR 1.08 (95% CI 0.82-1.41); noninferior Ctrough (GMR 1.05, 90% CI 0.88-1.24)	^[8]^A1b

Prognosis and Prognostic Factors

▸Prognosis in NSCLC is determined by stage, molecular subtype, histology, and biomarker dynamics; the 5-year OS for advanced disease historically <10% but now exceeds 60% in ALK-positive patients treated with alectinib [165].
▸Adjuvant osimertinib in EGFR-mutated stage IB-IIIA disease yields 4-year DFS rates of 70% versus 29% with placebo (HR 0.23) [145].
▸High-risk features such as TP53 co-mutations, lack of ctDNA clearance, and baseline brain metastases can be partially overcome by next-generation targeted therapies like amivantamab-lazertinib and lorlatinib [132,159].

HY High Yield: In ALK-positive advanced NSCLC, the 5-year PFS rate with lorlatinib is 60% (HR 0.19 vs crizotinib), the longest PFS ever reported for a single-agent targeted therapy in NSCLC [159].

HY High Yield: For EGFR-mutant NSCLC with TP53 co-mutation or detectable ctDNA, amivantamab-lazertinib significantly improves PFS over osimertinib (HR 0.65 and 0.68, respectively) [132].

The past decade's therapeutic advances have reshaped survival expectations, but prognosis still varies widely by stage, molecular profile, and host factors. Historically, the 5-year survival rate among individuals with advanced/metastatic NSCLC has been <10% ^[67]^A1b. Modern treatment has improved these outcomes, yet the heterogeneity of the disease demands a nuanced understanding of the factors that stratify risk beyond the stage.

Overall Survival by Stage

For resected stage IB-IIIA EGFR-mutated NSCLC, adjuvant osimertinib dramatically alters the natural history. In the ADAURA trial, the 4-year disease-free survival (DFS) rate was 70% with osimertinib versus 29% with placebo in stage II-IIIA disease (HR 0.23, 95% CI 0.18-0.30) ^[145]^A1b. For unresectable stage III EGFR-mutated NSCLC, the LAURA study showed that osimertinib after chemoradiotherapy reduced the risk of CNS progression by (HR 0.17, 95% CI 0.09-0.32) and the cumulative incidence of distant metastases at 12 months was 11% versus 37% with placebo ^[9]^A1b. In the metastatic setting, monotherapy for PD-L1 tumor proportion score (TPS) ≥50% yields a median overall survival (OS) of 26.3 months and a 5-year OS rate of 31.9%, compared with 13.4 months and 16.3% for chemotherapy (HR 0.62, 95% CI 0.48-0.81) ^[168]^A1b. When pembrolizumab is combined with pemetrexed-platinum in nonsquamous disease, the median OS extends to 22.0 months versus 10.7 months (HR 0.56, 95% CI 0.45-0.70) ^[13]^A1b.

Molecular Prognostic Factors

EGFR mutations define a subgroup with distinct outcomes. In the first-line setting, the third-generation TKI aumolertinib achieved a median progression-free survival (PFS) of 19.3 months versus 9.9 months with gefitinib (HR 0.46, 95% CI 0.36-0.60) ^[169]^A1b. Among patients with EGFR-mutant advanced NSCLC and high-risk features (TP53 co-mutations, detectable ctDNA, baseline liver metastases), amivantamab-lazertinib outperformed osimertinib: median PFS 18.2 versus 12.9 months in TP53 co-mutated patients (HR 0.65, 95% CI 0.48-0.87) ^[132]^A1b. For those who progress on EGFR-TKIs, a network meta-analysis identified ICI plus antiangiogenesis plus chemotherapy as the optimal strategy, with a PFS HR of 0.54 (95% CI 0.44-0.67) versus chemotherapy alone ^[170]^A1a.

ALK rearrangements confer the most favorable prognosis in the metastatic setting. In the ALEX trial, final OS analysis showed a median OS of 81.1 months with alectinib versus 54.2 months with crizotinib (HR 0.78, 95% CI 0.56-1.08); the 5-year OS rate was 62.5% ^[165]^A1b. The CROWN study set a new benchmark: median PFS was not reached with lorlatinib after a median follow-up of 60.2 months, and the 5-year PFS rate was 60% (95% CI 51-68) versus 8% with crizotinib (HR 0.19, 95% CI 0.13-0.27) ^[159]^A1b.

PD-L1 expression is a critical prognostic and predictive biomarker. In KEYNOTE-024 (PD-L1 TPS ≥50%), pembrolizumab monotherapy yielded a median OS of 30.0 months versus 14.2 months with chemotherapy (HR 0.63, 95% CI 0.47-0.86) ^[146]^A1b. The benefit is amplified in the combination: KEYNOTE-189 showed a median OS of 22.0 months irrespective of PD-L1 level, with a 5-year OS rate of approximately 31.9% in the TPS ≥50% subgroup ^[13]^A1b^[168]^A1b.

Histology and Other High-Risk Features

Histologic subtype is an independent prognostic factor. In the TROPION-Lung01 study, datopotamab deruxtecan versus showed a significant PFS benefit only in nonsquamous histology (median PFS 5.5 versus 3.6 months; HR 0.63, 95% CI 0.51-0.79), while in squamous histology, docetaxel was numerically superior (HR 1.41, 95% CI 0.95-2.08) ^[67]^A1b. This histology-dependent effect was also reflected in OS: nonsquamous patients had a median OS of 14.6 months versus 12.3 months (HR 0.84, 95% CI 0.68-1.05), whereas squamous patients had 7.6 months versus 9.4 months (HR 1.32) ^[67]^A1b.

worsen prognosis, but targeted therapies can mitigate this. In the ALEX study, alectinib improved median OS in patients with baseline CNS metastases: 63.4 months versus 30.9 months with crizotinib (HR 0.68, 95% CI 0.40-1.15) ^[165]^A1b. The LAURA trial showed that osimertinib after chemoradiotherapy for stage III EGFR-mutated NSCLC reduced CNS progression risk by (HR 0.17) ^[9]^A1b.

TP53 co-mutations and ctDNA dynamics are emerging powerful prognostic factors. In the MARIPOSA study, patients with TP53 co-mutations had a median PFS of 18.2 months with amivantamab-lazertinib versus 12.9 months with osimertinib (HR 0.65), and those without ctDNA clearance at cycle 3 day 1 had a median PFS of 16.5 versus 9.1 months (HR 0.49) ^[132]^A1b.

Prognostic Factors Table

Factor	Favorable	Unfavorable	Evidence Source
Molecular subtype	ALK rearrangement, EGFR mutation (especially exon 19 deletion)	No actionable driver; KRAS mutation	^[159]^A1b, ^[165]^A1b, ^[169]^A1b
PD-L1 TPS	≥50% (pembrolizumab benefit)	<1% (limited immunotherapy benefit)	^[168]^A1b, ^[146]^A1b
Histology	Nonsquamous	Squamous (poorer response to many agents)	^[67]^A1b
Brain metastases	Controlled with targeted therapy (e.g., alectinib, osimertinib)	Uncontrolled, symptomatic	^[165]^A1b, ^[9]^A1b
TP53 co-mutation	Wild-type TP53	TP53 co-mutation (shorter PFS)	^[132]^A1b
ctDNA clearance at cycle 3	Clearance (longer PFS)	No clearance (shorter PFS)	^[132]^A1b
Stage at diagnosis	Stage I-IIIA (resectable)	Stage IIIB-IV (unresectable/metastatic)	^[145]^A1b

Pearl: The single most powerful prognostic factor in advanced NSCLC is the presence of an actionable driver mutation (EGFR, ALK, ROS1, etc.) and access to a matched targeted therapy; for ALK-positive disease, the 5-year PFS rate of 60% with lorlatinib ^[159]^A1b rivals outcomes seen in many early-stage solid tumors.

Special Populations

▸Older adults derive similar survival benefit from standard NSCLC therapy as younger patients, despite underrepresentation in clinical trials.
▸People living with HIV (PLWH) with NSCLC should receive standard cancer therapy per NCCN guidelines, with multidisciplinary management of drug-drug interactions and chronic health conditions.
▸CT-defined sarcopenia with elevated BMI increases risk of platinum-associated adverse events; carboplatin dosing should use CKD-EPI rather than Cockcroft-Gault GFR estimation.

! Warning: Carboplatin dosing based on Cockcroft-Gault GFR may overestimate renal function in patients with sarcopenia and elevated BMI, leading to excess dose and increased toxicity. Use CKD-EPI GFR for dosing in this population [79].

Prognosis in NSCLC is further modified by patient-specific factors that demand individualized management. Three special populations, older adults, people living with HIV (PLWH), and patients with sarcopenia and elevated body mass index (BMI), warrant distinct considerations in treatment planning.

Older Adults

Older adults account for 70% of cancer-related deaths but are underrepresented in clinical trials ^[171]^B2a. In practice-changing NSCLC trials, only 34% of enrolled patients were older adults, and representation was lower in immunotherapy-containing regimens (<40%) ^[171]^B2a. However, no difference in overall or progression-free survival was observed between older and younger adults in these trials ^[171]^B2a. Therefore, age alone should not preclude standard therapy. Careful assessment of comorbidity, functional status, and potential for treatment-related toxicity is essential. Sarcopenia, common in older adults, further modifies risk (see below).

People Living With HIV

PLWH are diagnosed with cancer at increased rates and generally have higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities ^[1]^A1c. The NCCN Guidelines for Cancer in PLWH provide specific recommendations for NSCLC management, including HIV management during cancer therapy, drug-drug interactions between antiretroviral treatments and cancer therapies, and supportive care ^[1]^A1c. Among PLWH with non-AIDS-defining cancers (NADCs) including NSCLC, the risk of new-onset grade ≥3 chronic health conditions is significantly higher (HR 2.94; P<.0001), particularly diabetes mellitus, myocardial infarction, and congestive heart failure ^[24]^B3b. Multidisciplinary care integrating oncology and HIV specialists is recommended.

Sarcopenia and Elevated Body Mass Index

CT-defined sarcopenia (low skeletal muscle index) combined with elevated BMI (≥25 kg/m²) is associated with increased risk of platinum-associated adverse events ^[79]^B3b. In a retrospective cohort, patients with both sarcopenia and elevated BMI had higher risk of grade ≥2 anemia (sHR 1.64; 95% CI 1.17-2.29), thrombocytopenia (sHR 2.25; 95% CI 1.16-4.36), and increased creatinine (sHR 2.72; 95% CI 1.45-5.13) ^[79]^B3b. This may be due to GFR misestimation: when Cockcroft-Gault-based GFR dictates a dose ≥25 mg higher than CKD-EPI GFR, risk of AEs and chemotherapy discontinuation increases ^[79]^B3b. Therefore, carboplatin dosing should be based on CKD-EPI rather than Cockcroft-Gault in patients with low muscle mass and elevated BMI.

Pearl: In older adults and PLWH, standard NSCLC therapy should not be withheld based on age or HIV status alone; however, careful attention to drug-drug interactions (in PLWH) and body composition-based chemotherapy dosing (in sarcopenic patients) is critical to optimize outcomes.

References

[1]
Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗
L1GUIDELINECited in: Definition and Epidemiology, Special Populations
[2]
Pang LL, Zhuang WT, Chen ZH et al.. “Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40081325 ↗
L1SR_MA_RCTCited in: Definition and Epidemiology, Management Overview
[3]
Pallis AG, Gridelli C, Wedding U et al.. “Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24638905 ↗
L1GUIDELINECited in: Definition and Epidemiology
[4]
Yan TD, Black D, Bannon PG et al.. “Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19289625 ↗
L1SR_MA_RCTCited in: Definition and Epidemiology
[5]
Khoja L, Day D, Wei-Wu Chen T et al.. “Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28945858 ↗
L2SR_COHORTCited in: Definition and Epidemiology, Histopathology and Molecular Biology
[6]
Dearden S, Stevens J, Wu YL et al.. “Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23723294 ↗
L2SR_COHORTCited in: Definition and Epidemiology, Histopathology and Molecular Biology
[7]
Johnson KR, Ringland C, Stokes BJ et al.. “Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.” The Lancet. Oncology (2006). PMID: 16945769 ↗
L1SR_MA_RCTCited in: Definition and Epidemiology
[8]
Burotto M, Zvirbule Z, Mochalova A et al.. “IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37268157 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment
[9]
Lu S, Ahn MJ, Reungwetwattana T et al.. “Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39289145 ↗
L1RCTCited in: Definition and Epidemiology, Staging, Prognosis and Prognostic Factors, Special Populations
[10]
Sugawara S, Lee JS, Kang JH et al.. “Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34139272 ↗
L1RCTCited in: Definition and Epidemiology
[11]
Shah NJ, Cook MR, Wu T et al.. “The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35830888 ↗
L4PROSPECTIVE_COHORTCited in: Definition and Epidemiology
[12]
Allen J, Jahanzeb M. “Neoadjuvant chemotherapy in stage III NSCLC.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18377847 ↗
L2NON_RANDOMIZED_TRIALCited in: Definition and Epidemiology, Staging
[13]
Gadgeel S, Rodríguez-Abreu D, Speranza G et al.. “Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32150489 ↗
L1RCTCited in: Definition and Epidemiology, Prognosis and Prognostic Factors, Special Populations
[14]
Wang Z, Wu L, Li B et al.. “Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36206498 ↗
L1RCTCited in: Definition and Epidemiology, Histopathology and Molecular Biology
[15]
Sun H, Li M, Huang W et al.. “Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39374473 ↗
L1RCTCited in: Definition and Epidemiology
[16]
Senan S, Brade A, Wang LH et al.. “PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26811519 ↗
L1RCTCited in: Definition and Epidemiology, Staging
[17]
Solomon BJ, Bauer TM, Ignatius Ou SH et al.. “Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35605188 ↗
L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention
[18]
Bousema JE, Dijkgraaf MGW, van der Heijden EHFM et al.. “Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37018653 ↗
L1RCTCited in: Definition and Epidemiology, Imaging
[19]
Pérol M, Solomon BJ, Goto K et al.. “CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38828957 ↗
L1RCTCited in: Definition and Epidemiology
[20]
Hussaini S, Chehade R, Boldt RG et al.. “Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 33302134 ↗
L4SR_COHORTCited in: Definition and Epidemiology
[21]
Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[22]
Dammeijer F, Lievense LA, Veerman GD et al.. “Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27432922 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[23]
Lee CK, Wu YL, Ding PN et al.. “Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25897154 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[24]
Goyal G, Enogela EM, Burkholder GA et al.. “Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40490015 ↗
L3RETROSPECTIVE_COHORTCited in: Risk Factors and Prevention, Special Populations
[25]
Lee SH, Menis J, Kim TM et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer.” ESMO open (2024). PMID: 39615406 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, History and Evolution of Treatment
[26]
Funakoshi T, Suzuki M, Tamura K. “Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.” Cancer treatment reviews (2014). PMID: 25288497 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[27]
Landré T, Karaboué A, Buchwald ZS et al.. “Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.” ESMO open (2024). PMID: 38232612 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[28]
Conforti F, Pala L, Bagnardi V et al.. “Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29778737 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[29]
Li N, Zeng ZF, Wang SY et al.. “Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25515658 ↗
L1RCTCited in: Risk Factors and Prevention
[30]
Mitchell P, Thatcher N, Socinski MA et al.. “Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25722382 ↗
L1RCTCited in: Risk Factors and Prevention
[31]
Al-Batran SE, Hozaeel W, Tauchert FK et al.. “The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25755108 ↗
L3COHORTCited in: Risk Factors and Prevention
[32]
Wink KCJ, van Baardwijk A, Troost EGC et al.. “Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.” Cancer treatment reviews (2017). PMID: 28437679 ↗
L2SR_COHORTCited in: Risk Factors and Prevention, Imaging
[33]
Hoang TCT, Debieuvre D, Bravard AS et al.. “Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.” ESMO open (2024). PMID: 38848661 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Prevention
[34]
Li M, Hou X, Zheng L et al.. “Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.” ESMO open (2021). PMID: 34922300 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Prevention
[35]
Coelho AL, Gomes MP, Catarino RJ et al.. “CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lung cancer.” ESMO open (2018). PMID: 30094067 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Prevention
[36]
Gomes F, Lorigan P, Woolley S et al.. “A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study.” ESMO open (2021). PMID: 33516147 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Prevention
[37]
Jamal-Hanjani M, Wilson GA, McGranahan N et al.. “Tracking the Evolution of Non-Small-Cell Lung Cancer.” The New England journal of medicine (2017). PMID: 28445112 ↗
L2PROSPECTIVE_COHORTCited in: Risk Factors and Prevention
[38]
Reck M, Kaiser R, Mellemgaard A et al.. “Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.” The Lancet. Oncology (2014). PMID: 24411639 ↗
L1RCTCited in: Risk Factors and Prevention
[39]
Wu YL, Zhou C, Hu CP et al.. “Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.” The Lancet. Oncology (2014). PMID: 24439929 ↗
L1RCTCited in: Risk Factors and Prevention
[40]
Ettinger DS, Wood DE, Akerley W et al.. “Non-Small Cell Lung Cancer, Version 6.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25964637 ↗
L1GUIDELINECited in: Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment
[41]
Sugawara S, Oizumi S, Minato K et al.. “Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25669832 ↗
L2RCT_PHASE2Cited in: Genetics and Hereditary Predisposition
[42]
Viñal D, Martínez D, Higuera O et al.. “Genomic profiling in non-small-cell lung cancer in young patients. A systematic review.” ESMO open (2021). PMID: 33516149 ↗
L2SR_COHORTCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
[43]
Shaw AT, Solomon B, Kenudson MM. “Crizotinib and testing for ALK.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 22157554 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
[44]
Mascaux C, Tsao MS, Hirsch FR. “Genomic Testing in Lung Cancer: Past, Present, and Future.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29523671 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[45]
Soria JC, Wu YL, Nakagawa K et al.. “Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.” The Lancet. Oncology (2015). PMID: 26159065 ↗
L1RCTCited in: Genetics and Hereditary Predisposition
[46]
Wu YL, Lee JS, Thongprasert S et al.. “Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.” The Lancet. Oncology (2013). PMID: 23782814 ↗
L2RCT_PHASE2Cited in: Genetics and Hereditary Predisposition
[47]
Haratani K, Hayashi H, Tanaka T et al.. “Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28407039 ↗
L3RETROSPECTIVE_COHORTCited in: Genetics and Hereditary Predisposition
[48]
Kanwar N, Seyi AB, Tan N et al.. “From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671451 ↗
L4CASE_SERIESCited in: Genetics and Hereditary Predisposition
[49]
Sukari A, Nagasaka M, Wakeling E. “EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28982744 ↗
L4CASE_SERIESCited in: Genetics and Hereditary Predisposition
[50]
Lammers PE, Lovly CM, Horn L. “A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24453288 ↗
L4CASE_SERIESCited in: Genetics and Hereditary Predisposition
[51]
Wu J, Liu J, Zhou Y et al.. “Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22705987 ↗
L2SR_COHORTCited in: Genetics and Hereditary Predisposition
[52]
Guan S, Chen X, Chen Y et al.. “FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35695863 ↗
L1RCTCited in: Genetics and Hereditary Predisposition
[53]
O'Byrne KJ, Gatzemeier U, Bondarenko I et al.. “Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.” The Lancet. Oncology (2011). PMID: 21782507 ↗
L2NON_RANDOMIZED_TRIALCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
[54]
Tan AC, Tan DSW. “Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34985916 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[55]
Subbiah V, Yang D, Velcheti V et al.. “State-of-the-Art Strategies for Targeting RET-Dependent Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32083997 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[56]
Subramanian J, Govindan R. “Lung cancer in never smokers: a review.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17290066 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[57]
Li T, Kung HJ, Mack PC et al.. “Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23401433 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[58]
Sequist LV, Bell DW, Lynch TJ et al.. “Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17290067 ↗
L5NARRATIVE_REVIEWCited in: Genetics and Hereditary Predisposition
[59]
Aggarwal C, Thompson JC, Black TA et al.. “Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.” JAMA oncology (2019). PMID: 30325992 ↗
L4PROSPECTIVE_COHORTCited in: Genetics and Hereditary Predisposition
[60]
Grossman SA, Ellsworth S, Campian J et al.. “Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26483062 ↗
L2SR_COHORTCited in: Histopathology and Molecular Biology, Special Populations
[61]
Tang H, Wang S, Xiao G et al.. “Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28200038 ↗
L2SR_COHORTCited in: Histopathology and Molecular Biology
[62]
Rossi G, Barcellini L, Tagliamento M et al.. “Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.” ESMO open (2025). PMID: 40913837 ↗
L1SR_MA_RCTCited in: Histopathology and Molecular Biology
[63]
Siciliano MA, Caridà G, Ciliberto D et al.. “Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.” ESMO open (2022). PMID: 35427835 ↗
L1SR_MA_RCTCited in: Histopathology and Molecular Biology, Clinical Presentation
[64]
Coudert B, Ciuleanu T, Park K et al.. “Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21610154 ↗
L1RCTCited in: Histopathology and Molecular Biology
[65]
Weiss GJ, Rosell R, Fossella F et al.. “The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17322539 ↗
L1RCTCited in: Histopathology and Molecular Biology
[66]
Syrigos KN, Vansteenkiste J, Parikh P et al.. “Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19828561 ↗
L1RCTCited in: Histopathology and Molecular Biology
[67]
Ahn MJ, Tanaka K, Paz-Ares L et al.. “Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39250535 ↗
L1RCTCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors, Special Populations
[68]
Socinski MA, Bondarenko I, Karaseva NA et al.. “Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22547591 ↗
L1RCTCited in: Histopathology and Molecular Biology
[69]
Scagliotti GV, Parikh P, von Pawel J et al.. “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18506025 ↗
L1RCTCited in: Histopathology and Molecular Biology
[70]
Paz-Ares LG, Juan-Vidal O, Mountzios GS et al.. “Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38843511 ↗
L1RCTCited in: Histopathology and Molecular Biology
[71]
Strauss GM, Herndon JE, Maddaus MA et al.. “Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18809614 ↗
L1RCTCited in: Histopathology and Molecular Biology
[72]
Scagliotti GV, Parikh P, von Pawel J et al.. “Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37146426 ↗
L1RCTCited in: Histopathology and Molecular Biology
[73]
Chiappori AA, Kolevska T, Spigel DR et al.. “A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25467017 ↗
L2RCT_PHASE2Cited in: Histopathology and Molecular Biology
[74]
Di Federico A, Stumpo S, Mantuano F et al.. “Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.” The Lancet. Oncology (2025). PMID: 41038207 ↗
L2SR_COHORTCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[75]
Nardi EA, Sun CL, Robert F et al.. “Lung Cancer in Nonelderly Patients: Facility and Patient Characteristics Associated With Not Receiving Treatment.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390587 ↗
L3RETROSPECTIVE_COHORTCited in: Histopathology and Molecular Biology, Clinical Presentation
[76]
Riely GJ, Wood DE, Ettinger DS et al.. “Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38754467 ↗
L1GUIDELINECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[77]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545176 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview
[78]
Riely GJ, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41956107 ↗
L1GUIDELINECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
[79]
Lyu J, Mantz L, Katz-Agranov NS et al.. “Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40738140 ↗
L3RETROSPECTIVE_COHORTCited in: Clinical Presentation, Special Populations
[80]
Arrato NA, Lo SB, Coker CA et al.. “Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non-Small Cell Lung Cancer Versus Community Controls.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35130505 ↗
L3COHORTCited in: Clinical Presentation
[81]
Bagley SJ, Talento S, Mitra N et al.. “Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085759 ↗
L3RETROSPECTIVE_COHORTCited in: Clinical Presentation
[82]
Gross CP, Meyer CS, Ogale S et al.. “Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545174 ↗
L3COHORTCited in: Clinical Presentation
[83]
Soon YY, Stockler MR, Askie LM et al.. “Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19470938 ↗
L1SR_MA_RCTCited in: Clinical Presentation
[84]
Zheng MM, Xia Y, Pan K et al.. “The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41125209 ↗
L3RETROSPECTIVE_COHORTCited in: Clinical Presentation
[85]
Greer JA, Post KE, Chabria R et al.. “Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39088766 ↗
L1RCTCited in: Clinical Presentation, Staging
[86]
Yajima S, Hirose K, Masuda H. “Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis.” Cancer treatment reviews (2025). PMID: 41242178 ↗
L2SR_COHORTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
[87]
Peters S, Bexelius C, Munk V et al.. “The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.” Cancer treatment reviews (2016). PMID: 27019457 ↗
L2SR_COHORTCited in: Clinical Presentation
[88]
Lurain K. “Treating Cancer in People With HIV.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37267514 ↗
L3COHORTCited in: Clinical Presentation
[89]
Horn L. “Advances in the treatment of non-small cell lung cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853212 ↗
L5NARRATIVE_REVIEWCited in: Clinical Presentation
[90]
Vijayvergia N, Shah PC, Denlinger CS. “Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26358799 ↗
L5NARRATIVE_REVIEWCited in: Clinical Presentation
[91]
Ganti AK, deShazo M, Weir AB et al.. “Treatment of non-small cell lung cancer in the older patient.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22308517 ↗
L5NARRATIVE_REVIEWCited in: Clinical Presentation
[92]
Temel JS, Abernethy AP, Currow DC et al.. “Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.” The Lancet. Oncology (2016). PMID: 26906526 ↗
L1RCTCited in: Clinical Presentation
[93]
Eberhardt WE, De Ruysscher D, Weder W et al.. “2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25897013 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Imaging
[94]
Paz-Ares L, Spira A, Raben D et al.. “Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32209338 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis
[95]
Azzoli CG, Baker S, Temin S et al.. “American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19917871 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis
[96]
de Marinis F, Kim TM, Bonanno L et al.. “Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40461383 ↗
L2RCT_PHASE2Cited in: Biopsy and Histologic Diagnosis, Special Populations
[97]
Cappuzzo F, Ciuleanu T, Stelmakh L et al.. “Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.” The Lancet. Oncology (2010). PMID: 20493771 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis
[98]
Pirker R, Pereira JR, von Pawel J et al.. “EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.” The Lancet. Oncology (2011). PMID: 22056021 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis
[99]
Cho BC, Abreu DR, Hussein M et al.. “Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.” The Lancet. Oncology (2022). PMID: 35576957 ↗
L2RCT_PHASE2Cited in: Biopsy and Histologic Diagnosis
[100]
Meric-Bernstam F, Makker V, Oaknin A et al.. “Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37870536 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[101]
Heist RS, Guarino MJ, Masters G et al.. “Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28548889 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[102]
Simon G, Sharma A, Li X et al.. “Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17602079 ↗
L4NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[103]
Lim SM, Kim HR, Lee JS et al.. “Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28520527 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[104]
Schuler M, Berardi R, Lim WT et al.. “Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32240796 ↗
L4PHASE_1_TRIALCited in: Biopsy and Histologic Diagnosis
[105]
Galffy G, Lugowska I, Poddubskaya EV et al.. “A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.” ESMO open (2023). PMID: 37141847 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[106]
Smit EF, Felip E, Uprety D et al.. “Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38547891 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[107]
Quoix E, Ramlau R, Westeel V et al.. “Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.” The Lancet. Oncology (2011). PMID: 22019520 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[108]
Forde PM, Chaft JE, Smith KN et al.. “Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.” The New England journal of medicine (2018). PMID: 29658848 ↗
L2NON_RANDOMIZED_TRIALCited in: Biopsy and Histologic Diagnosis
[109]
Hayashi H, Takiguchi Y, Minami H et al.. “Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.” JAMA oncology (2020). PMID: 33057591 ↗
L2RCT_PHASE2Cited in: Biopsy and Histologic Diagnosis
[110]
Garon EB, Hellmann MD, Rizvi NA et al.. “Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31154919 ↗
L4PHASE_1_TRIALCited in: Biopsy and Histologic Diagnosis
[111]
Jazieh AR, Bamefleh H, Demirkazik A et al.. “Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697125 ↗
L1GUIDELINECited in: Imaging, Staging
[112]
Park K, Vansteenkiste J, Lee KH et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31959336 ↗
L1GUIDELINECited in: Imaging
[113]
Vansteenkiste J, Crinò L, Dooms C et al.. “2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24562446 ↗
L1GUIDELINECited in: Imaging, Staging
[114]
Felip E, Altorki N, Zhou C et al.. “Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37467930 ↗
L1RCTCited in: Imaging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[115]
Gadgeel S, Peters S, Mok T et al.. “Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30215676 ↗
L1RCTCited in: Imaging
[116]
Daly ME, Singh N, Ismaila N et al.. “Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34936470 ↗
L1RCTCited in: Imaging
[117]
Stinchcombe TE, Wang X, Damman B et al.. “Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38215351 ↗
L1RCTCited in: Imaging
[118]
Akinboro O, Drezner N, Amatya A et al.. “US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37141544 ↗
L1RCTCited in: Imaging
[119]
Costa DB, Shaw AT, Ou SH et al.. “Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25624436 ↗
L1RCTCited in: Imaging
[120]
Bollineni VR, Wiegman EM, Pruim J et al.. “Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy.” Cancer treatment reviews (2012). PMID: 22560366 ↗
L2SR_COHORTCited in: Imaging
[121]
O'Brien M, Paz-Ares L, Marreaud S et al.. “Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36108662 ↗
L1RCTCited in: Imaging
[122]
Bradley JD, Paulus R, Komaki R et al.. “Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.” The Lancet. Oncology (2015). PMID: 25601342 ↗
L1RCTCited in: Imaging
[123]
Westeel V, Foucher P, Scherpereel A et al.. “Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2022). PMID: 35964621 ↗
L1RCTCited in: Imaging
[124]
Nestle U, Schimek-Jasch T, Kremp S et al.. “Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.” The Lancet. Oncology (2020). PMID: 32171429 ↗
L1RCTCited in: Imaging
[125]
Blanchon F, Grivaux M, Asselain B et al.. “4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index.” The Lancet. Oncology (2006). PMID: 17012045 ↗
L1RCTCited in: Imaging
[126]
Wakelee HA, Dahlberg SE, Keller SM et al.. “Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.” The Lancet. Oncology (2017). PMID: 29129443 ↗
L1RCTCited in: Imaging
[127]
Heymach JV, Harpole D, Mitsudomi T et al.. “Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.” The New England journal of medicine (2023). PMID: 37870974 ↗
L1RCTCited in: Imaging
[128]
Ettinger DS, Akerley W, Borghaei H et al.. “Non-small cell lung cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 23054877 ↗
L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[129]
Ettinger DS, Wood DE, Aisner DL et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33668021 ↗
L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
[130]
Ettinger DS, Aisner DL, Wood DE et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30006423 ↗
L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
[131]
Hong SD, Wang YS, Zhao HY et al.. “Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41611210 ↗
L1SR_MA_RCTCited in: Molecular Diagnostics and Biomarkers, Special Populations
[132]
Felip E, Cho BC, Gutiérrez V et al.. “Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38942080 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[133]
Schneider BJ, Ismaila N, Aerts J et al.. “Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31829901 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[134]
Luo J, Wu S, Rizvi H et al.. “Deciphering radiological stable disease to immune checkpoint inhibitors.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35533926 ↗
L2SR_COHORTCited in: Molecular Diagnostics and Biomarkers
[135]
Goto K, Goto Y, Kubo T et al.. “Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37694347 ↗
L2RCT_PHASE2Cited in: Molecular Diagnostics and Biomarkers
[136]
Olaussen KA, Dunant A, Fouret P et al.. “DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.” The New England journal of medicine (2006). PMID: 16957145 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[137]
Goldberg SB, Schalper KA, Gettinger SN et al.. “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2020). PMID: 32251621 ↗
L2RCT_PHASE2Cited in: Molecular Diagnostics and Biomarkers
[138]
Shaw AT, Solomon BJ, Besse B et al.. “ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30892989 ↗
L2NON_RANDOMIZED_TRIALCited in: Molecular Diagnostics and Biomarkers
[139]
Karachaliou N, Mayo-de las Casas C, Queralt C et al.. “Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.” JAMA oncology (2015). PMID: 26181014 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[140]
Wang X, Lee DH, Yang SC et al.. “Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41072474 ↗
L3RETROSPECTIVE_COHORTCited in: Molecular Diagnostics and Biomarkers, Special Populations
[141]
Yu HA, Baik C, Kim DW et al.. “Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38369013 ↗
L4PHASE_1_TRIALCited in: Molecular Diagnostics and Biomarkers
[142]
Reuss JE, Kuruvilla S, Ismaila N et al.. “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40674661 ↗
L1GUIDELINECited in: Staging
[143]
Owen DH, Halmos B, Puri S et al.. “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40674687 ↗
L1GUIDELINECited in: Staging
[144]
Aupérin A, Le Péchoux C, Rolland E et al.. “Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20351327 ↗
L1SR_MA_RCTCited in: Staging, Management Overview
[145]
Herbst RS, Wu YL, John T et al.. “Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36720083 ↗
L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
[146]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30620668 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors, Special Populations
[147]
Felip E, Altorki N, Zhou C et al.. “Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40446184 ↗
L1RCTCited in: Staging
[148]
Bradley JD, Hu C, Komaki RR et al.. “Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31841363 ↗
L1RCTCited in: Staging
[149]
Bradley JD, Sugawara S, Lee KH et al.. “Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41082707 ↗
L1RCTCited in: Staging
[150]
Kenmotsu H, Yamamoto N, Yamanaka T et al.. “Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32407216 ↗
L1RCTCited in: Staging
[151]
Patel JD, Socinski MA, Garon EB et al.. “PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145346 ↗
L1RCTCited in: Staging
[152]
Hoffner B, Leighl NB, Davies M. “Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.” Cancer treatment reviews (2020). PMID: 32078962 ↗
L1SR_MA_RCTCited in: Staging
[153]
Bria E, Cuppone F, Ciccarese M et al.. “Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.” Cancer treatment reviews (2006). PMID: 16919884 ↗
L1SR_MA_RCTCited in: Staging
[154]
Riely GJ, Wood DE, Aisner DL et al.. “NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40930154 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[155]
Ettinger DS, Akerley W, Borghaei H et al.. “Non-small cell lung cancer, version 2.2013.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23744864 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[156]
Mosele MF, Westphalen CB, Stenzinger A et al.. “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38834388 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[157]
Mok T, Camidge DR, Gadgeel SM et al.. “Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32418886 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[158]
Felip E, Rojas CI, Schenker M et al.. “Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40157574 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
[159]
Solomon BJ, Liu G, Felip E et al.. “Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38819031 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[160]
Novello S, Kowalski DM, Luft A et al.. “Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36735893 ↗
L1RCTCited in: Management Overview
[161]
Spigel DR, Faivre-Finn C, Gray JE et al.. “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35108059 ↗
L1RCTCited in: Management Overview
[162]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404761 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
[163]
Passaro A, Leighl N, Blackhall F et al.. “ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35176458 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[164]
Rodríguez-Abreu D, Powell SF, Hochmair MJ et al.. “Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33894335 ↗
L1RCTCited in: History and Evolution of Treatment
[165]
Peters S, Camidge R, Dziadziuszko R et al.. “Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41110693 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[166]
Besse B, Felip E, Garcia Campelo R et al.. “Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37704166 ↗
L1RCTCited in: Prognosis and Prognostic Factors
[167]
Leighl NB, Akamatsu H, Lim SM et al.. “Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38857463 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
[168]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33872070 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
[169]
Lu S, Dong X, Jian H et al.. “AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35580297 ↗
L1RCTCited in: Prognosis and Prognostic Factors
[170]
Zhao Y, He Y, Wang W et al.. “Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.” The Lancet. Oncology (2024). PMID: 39159630 ↗
L1SR_MA_RCTCited in: Prognosis and Prognostic Factors
[171]
Chow R, Lage DE, Williams GR et al.. “Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 34991068 ↗
L2SR_COHORTCited in: Special Populations
[172]
Wang C, Wang W, Liu H et al.. “Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41344593 ↗
L1RCTCited in: Special Populations
[173]
He J, Tsuboi M, Weder W et al.. “Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40454705 ↗
L1RCTCited in: Special Populations

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition and Epidemiology

Risk Factors and Prevention

Established Risk Factors

Prevention

Genetics and Hereditary Predisposition

Recognized Hereditary Lung Cancer Syndromes

When to Suspect a Germline Mutation

Guidelines for Germline Testing

Clinical Implications

Histopathology and Molecular Biology

Histologic Subtypes

Molecular Drivers

Prognostic Gene Expression Signatures

Clinical Presentation

Symptoms

Signs

Red Flags and Atypical Presentations

Biopsy and Histologic Diagnosis

Tissue Acquisition

Histologic Classification

Role of Immunohistochemistry

Adequacy for Molecular Testing

Imaging

Imaging for Staging

PET for Radiotherapy Planning

Surveillance Imaging

Brain Imaging in Advanced Disease

Imaging for Staging

Surveillance After Curative Resection

Molecular Diagnostics and Biomarkers

Indications and Recommendations

Testing Modalities and Turnaround Time

Key Actionable Biomarkers

Liquid Biopsy

Novel Biomarkers Under Evaluation

Staging

TNM Stage Groupings (8th Edition)

Clinical Implications by Stage Group

Management Overview

Risk Stratification and Initial Assessment

Early-Stage NSCLC (Stage I-IIIA)

Locally Advanced NSCLC (Stage III)

Advanced or Metastatic NSCLC (Stage IV)

Special Considerations: Brain Metastases

History and Evolution of Treatment

The Chemotherapy Era

The Targeted Therapy Revolution

The Immunotherapy Era

Recent Innovations: Subcutaneous Formulations and Combination Strategies

What Was Abandoned and Why

Prognosis and Prognostic Factors

Overall Survival by Stage

Molecular Prognostic Factors

Histology and Other High-Risk Features

Prognostic Factors Table

Special Populations

Older Adults

People Living With HIV

Sarcopenia and Elevated Body Mass Index

References

Special Considerations: